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CHAPTER I 
INTRODUCTION 
- EFFECTS OF NUTRIENTS ON PLASMA CHOLECYSTOKININ RELEASE 
- THE ROLE OF CHOLECYSTOKININ IN GALLBLADDER CONTRACTION 
IN RESPONSE TO NUTRIENTS 
- AIMS AND OUTLINE OF THE STUDIES PRESENTED IN THIS THESIS 
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EFFECTS OF NUTRIENTS ON PLASMA CHOLCYSTOKININ RELEASE 
Cholecystokimn (CCK) is a polypeptide that has been isolated 
and chemically indentified from hog intestinal mucosa by Mutt and 
Jorpes (1). It consists of 33 amino acids residues (1). Cholecys­
tokimn is a strong stimulant of pancreatic enzyme secretion and 
gallbladder contraction. 
At present two other molecular forms of CCK containing 39 (2) 
and 58 (3) amino acids residues have been chemically characte­
rized. Immunoreactive material eluting in a similar position in 
column chromatography as the C-terminal octapeptide of CCK (ССК ) 
has been identified in the small intestine, but it 13 not yet 
known whether the structure is identical to ССК (4). Recent stu­
dies have shown that cholecystokimn both in tissue and plasma is 
present m different molecular forms (5-13)· Radioimmunoassays 
and immunohistochemical studies have demonstrated the presence of 
CCK in nervous tissue and mucosa of the gastrointestinal tract 
(ІЗ-І9). CCK in gut is present in endocrine cells (15,16). There 
is a good agreement between immunohistochemical, radioimmunoassay 
and bioassay studies regarding tissue localization of CCK. Thus, 
CCK cells occur in highest numbers in the duodenum and proximal 
jejunum of adult mammals (4,5,8,9, 12,14,19). They are sparse in 
the ileum and virtually absent from the rest of the gut 
(5,14,15)· Large amounts of CCK immunoreact1 vity are found in hog 
and human duodenum (5,8,9,14,15)· Gel filtration reveals peaks 
corresponding to CCK33 and CCK8 as well as peaks larger than 
CCK33, between CCK33 and CCK8, and possibly smaller than CCK8 
(5,8,9,12,14). The CCK cell corresponds to the I cell identified 
by electron microscopy (17). 
The processes which occur between the release of CCK in the 
intestine and stimulation of pancreatic enzyme secretion and 
gallbladder contraction are not yet elucidated. Most studies of 
CCK release have involved in vivo measurement of pancreatic pro­
tein or enzyme secretion and have assumed that the responses ob­
tained are due to circulating CCK. Experiments using pancreatic 
enzyme secretion as a bioassay system for plasma CCK indicate 
that products of fat and protein digestion are effective relea-
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sers of CCK. In dogs with a subcutaneously autotransplanted pan-
creas Wang (1951) found that pancreatic enzyme secretion was sti-
mulated by intraduodenal instillation of corn oil, whereas mal-
tose and dextrose were ineffective (20). In dogs with gastric and 
pancreatic fistulas it was found that intraduodenal perfusion of 
micellar solutions of fatty acids of more than 9 carbon atoms in 
chain length and monooleate stimulated pancreatic enzyme secre-
tion (21). Triglycerides as such did not stimulate enzyme secre-
tion unless preceded by lipolysis. Using the same model Meyer and 
coworkers demonstrated that intraintestinal perfusion of peptic 
digests of proteins, some oligopeptides and some L-amino acids 
elicited pancreatic enzyme secretion (22-24). Also in man it was 
demonstrated that products of fat digestion, e.g. micellar solu-
tions of monooleine, oleic acid and lauric acid, and the essen-
tial L-amino acids phenylanine, methionine, valine and possibly 
tryptophan were potent stimuli of pancreatic enzyme secretion 
suggesting CCK release (25-27). Perfusion of dextrose, normal sa-
line or glycerol into the upper gastrointestinal tract did not 
stimulate pancreatic enzyme secretion indicating failure of CCK 
release (25-27). Intraluminal calcium salts may cause CCK release 
in man, while magnesium salts appeared to be weak stimulants 
(28,29). Both in man and dog it is suggested that the length of 
proximal intestine exposed to an intraluminal stimulant is pro-
portional to the amount of pancreatic enzyme output (24,27)· 
Apart from the sometimes unphysiologic stimuli applied in the 
above mentioned experiments, these studies only provide indirect 
evidence for CCK release. This is the more important since recent 
studies in dogs strongly suggest the existence of an enteropan-
creatic reflex which accounts at least in part for the intestinal 
phase of pancreatic enzyme secretion (32). Also the existence of 
an enterocystic reflex has been suggested mediating gallbladder 
response to intraintestinal stimuli (87). 
The finding that pancreatic responses to endogenous stimu-
lants are decreased by vagotomy and by administration of atropine 
is indicative of neural mechanisms in regulating pancreatic se-
cretion (30,31,33-39). Since the effect of exogenous CCK on pan-
creatic enzyme secretion was not inhibited by vagotomy or atro-
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pine, this was taken as evidence that CCK release is dependent on 
vagal innervation (30,38,39). On the other hand, Singer et al. 
demonstrated that atropine administration or vagotomy decreased 
the pancreatic responses to endogenous stimulation of the intact 
pancreas, but had no effect in a transplanted segment of pancreas 
in the same dog indicating that vagotomy and atropine administra-
tion did not interfere with CCK release (31,33). However, the 
specificity of the autotransplanted pancreas as a technique to 
quantify plasma CCK levels can be seriously questioned, since it 
may respond to other humoral agents as well. Furthermore, the 
sensitivity of this bioassay system has never been reported . 
It is evident that the effect of different stimuli on CCK 
release and the neural control of CCK release can only be studied 
with a reliable method to quantitate CCK levels in plasma. At 
present this involves quantification of plasma CCK levels by 
radioimmunological techniques. 
THE ROLE OF CHOLECYSTOKININ IN GALLBLADDER CONTRACTION IN RESPON-
SE TO NUTRIENTS 
Although the hormonal control of the gallbladder by CCK is 
widely accepted, many aspects of this system are still poorly 
understood . In the early years of this century it was demonstrat-
ed by numerous investigators that the introduction of food, fat, 
egg yolk and meat into the duodenum induced evacuation of bile 
and increased the amplitude of gallbladder contractions (49,50). 
Intravenous administration of nutrients was not followed by chan-
ges in activity (50). In 1928 Ivy and Oldberg isolated a substan-
ce from porcine upper small intestinal mucosa which, when injec-
ted intravenously, induced contraction and evacuation of the 
gallbladder (51). Carotid-to-carotid cross-circulation experi-
ments in dog and transfusion experiments in man soon firmly esta-
blished the hormonal status of this agent (51). Ivy and Oldberg 
named this humoral agent cholecystokinm (51). In those years 
three steps sufficed to prove that a hormonal mechanism was 
involved in any physiologic event during digestion. First, a sti-
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mulua applied to a part of the gastrointestinal tract produces a 
response in a distant target. Second, the effect persists after 
severing all nervous connections between the site of stimulation 
and the target. Third, the physiologic event is mimicked by in­
jection of an extract of the part to which the stimulus had been 
applied, but not by extracts from other tissue (52). Now that 
gastrointestinal hormones are cnemically identified, it is essen­
tial to study whether the amount and kind of peptide hormone 
released in response to the stimulus can account for the observed 
response (52). This implies that infusion of exogenous hormone 
resulting in plasma levels similar to those observed after a meal 
reproduces the observed response to a meal (52). 
The cholecystokinetic activity of CCK33 and ССК has been es­
tablished in a number of different species using both in vivo and 
in vitro preparations. Although it was first believed that on a 
molar base CCK8 was more potent than CCK33 in inducing gallblad­
der contraction, recent studies have shown that all molecular 
forms of CCK known at present show similar biological activity 
(53,54). The classical and most frequently employed technique in 
man to measure gallbladder response to CCK has been oral chole­
cystography. Cholescmt igraphy and duodenal intubation with sub­
sequent aspiration of pancreaticobiliary juice are other methods 
to quantitate gallbladder contraction in man (58-64,103,104). 
Using these techniques it was found that both rapid and slow 
intravenous infusion of CCK33 or CCK8 induced gallbladder con­
traction. However, it is not known whether the doses of CCK 
needed to induce gallbladder contraction in these studies result 
in plasma levels within the physiological range. Thus it is not 
known whether effects of CCK are physiologic rather than pharma­
cologic effects. This problem can only be settled by specific 
measurement of plasma CCK levels. Because of the lack of a sensi­
tive and specific radioimmunoassay for CCK, the physiological 
plasma levels of this polypeptide hormone have not been determi­
ned. However, recently a number of radioimmunoassays for CCK have 
been developed which allow measurement of CCK in plasma under 
physiologic condition (7,11,40-44,105,106). Using these assays 
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the physiological and pathophysiological role of CCK in gallblad­
der contraction can be studied for the first time 
(10,45-48 , 106-108) . 
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Although some early reports suggested an effect of secretin on 
gallbladder contractility, it is now generally accepted that 
secretin, when given alone, does not affect gallbladder motility 
neither in vivo nor in vitro. Vasoactive inhibitory polypeptide 
(VIP), a peptide that is chemically related to secretin, has a 
potent inhibitory effect on basal and CCK-stimulated gallbladder 
motor activity (.49). This inhibitory effect has been observed in 
opposum, guinea pig and feline gallbladder in vivo, and the 
guinea pig gallbladder in vitro (49). The presence of VIP 
containing nerve fibers in the smooth muscle of the feline and 
human gallbladder suggests that it acts locally as a neurotrans­
mitter, rather than as a circulating hormone (49). The motility 
of the feline gallbladder in vivo was not influenced by glucagon 
(66). In man glucagon increased gallbladder size as assessed by 
oral cholecystography (67). In vitro, glucagon did not exhibit 
any excitatory or inhibitory effect on the human, or guinea pig 
gallbladder (49). A physiological role for glucagon is unlikely, 
because the doses required for relaxation of the gallbladder far 
exceed those required for glycogenesis (50). 
Intravenous infusion of bovine Pancreatic Polypeptide (PP) 
into man inhibited bilirubin output at plasma concentrations 
similar to those observed after a meal (68,69). In cholecyst-
ectomized subjects PP had no effect on bilirubin output indica­
ting that the effect of PP on bilirubin output was mediated by 
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the gallbladder (68). In conscious healthy pigs a dose related 
fall in gallbladder pressure and a significant reduction in bile 
output was observed following intravenous infusion of PP at phy-
siological plasma levels (70). In cholecystectomized pigs PP had 
no effect on bile output (70). These findings suggest that the 
amount of PP released postprandially may be sufficient to inhibit 
gallbladder contraction but has no effect on hepatic secretion of 
bile. Since PP did not exhibit any effect on basal or cholecysto-
kinin generated tension of isolated human gallbladder strips, PP 
probably exerts its action at a site remote from the gallbladder 
(71 ). 
Conflicting results have been reported on the effect of soma-
tostatin on gallbladder motor activity. Neither in vivo nor in 
vitro, somatostatin affected CCK8 or acetylcholine induced guinea 
pig gallbladder contraction (72). On the other hand, in man soma-
tostatin abolished CCK induced duodenal bilirubin output sugges-
ting a profound inhibition of gallbladder contraction (73). Bom-
besin has been reported to induce gallbladder contraction in man 
and dog (79,80). Bombesin probably exerts its action on the gall-
bladder by release of CCK (65,81). 
During the interdigesti ve state, contractions of the gallblad-
der were identified to be closely associated with the initial 
period of phase II of the interdigestive migrating contractions 
in the duodenum (74). In dogs intravenous infusion of raotilin -
during the interdigestive but not the digestive period - induced 
transient contractions in the gallbladder in association with 
interdigestive migratory contractions in the stomach and duodenum 
by an atropine sensitive mechanism (75,76). In conscious healthy 
pigs motilin increased gallbladder pressure (78). On the other 
hand, raotilin did not cause any contraction of the isolated rab-
bit and human gallbladder, nor did it alter the response to CCK 
(71(77). Thus, it seems that motilin exerts its action at sites 
remote from the gallbladder without directly affecting gallblad-
der muscle. 
The action of a single hormone can often be altered by the 
presence of an additional gut peptide. Secretin has been reported 
both to enhance and to inhibit CCK induced gallbladder contrac-
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Several observations suggest a role of the parasympathetic 
nervous system in control of gallbladder motility. Acetylcholine 
induces contraction of the in vitro gallbladder strip (49,50). 
Also human gallbladder strips respond to acetylcholine (82). In 
baboons pilocarpine induced a significant elevation of peak gall­
bladder pressure, which was prevented by atropine (83). Injection 
of a subthreshold dose of carbachol markedly stimulated contrac­
tion of the gallbladder in man after both truncal and selective 
vagotomy (84). Atropine and hexamethonium reduce intrabiliary 
pressure in the dog (85). Mean gallbladder volume in sphincter-
ectoraized prairy dogs after a four week treatment with atropine 
was larger than in control animals (86). In dogs graded disten­
sion of the antrum caused graded gallbladder contraction as evi­
denced by bilirubin output. This mechanism was abolished by atro­
pine or truncal vagotomy supplying evidence for a cholinergic, 
pylorocholecystic reflex that is dependent on intact long vagal 
pathways (87). Sham feeding has been reported to induce gallblad­
der contraction by an atropine sensitive mechanism in man 
(88,89). Insulin hypoglycemia induced a moderate contraction in 
patients with an intact vagal nerve supply of the gallbladder 
(84). A potentiating interaction between neural and hormonal 
influences on gallbladder motility has been suggested (90-92). 
The effect of vagotomy on gallbladder motility has been the 
subject of many studies. Total vagotomy was followed by an 
increase in gallbladder volume in man and dog (93-97). However, 
no change was reported in dogs 10 weeks after hepatic and coeliac 
18 
vagotomy (100). Highly selective vagotomy and selective vagotomy 
did not affect gallbladder volume m man and dog (94,96,98). In 
prairy dogs no change in intragalIbladder pressure after vagotomy 
was observed (101), whereas in anaesthetized cats vagal section 
decreased the resting pressure in the gallbladder (102). Exo-
genous CCK induced a greater increase in mtragallbladder pres-
sure in vagotomized dogs than in control animals without affec-
ting gallbladder emptying (101). Others reported the occurence of 
gallbladder contraction at a lower dose In patients with truncal 
vagotomy than In normal subjects. This increased sensitivity to 
exogenous CCK was not confirmed in dogs nor in anaesthetized cats 
(97,102). Although in patients with truncal vagotomy ingestion of 
a fatty meal was followed by less satisfactory emptying of the 
gallbladder (93), it is now generally accepted that truncal vago-
tomy does not inhibit gallbladder motility in response to intra-
luminal stimulants (49)· 
Stimulation of the sympathetic nervous sytem or injection of 
norepinephrine has a relaxing effect on the gallbladder, provided 
its pressure or tension is elevated by prior CCK or vagal stimu-
lation (49). Gallbladder smooth muscle contains both excitatory 
(alpha) and inhibitory (bèta) adrenergic receptors (49). The 
physiological significance of the inhibitory effect of adrenergic 
stimulation is not clear. 
The above mentioned observations point to a role of the 
autonomic nervous system in control of gallbladder tonus and 
gallbladder emptying. However, it is far from clear to what 
extent the autonomic nervous system contributes to gallbladder 
motor activity. Parasympathetic influences seem to be of a 
primary importance in maintaining the tone of the gallbladder, 
whereas they probably modulate gallbladder emptying induced by 
hormones . 
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AIMS AND OUTLINE OF THE STUDIES PRESENTED IN THIS THESIS 
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In chapter II the effect of oral ingestion of equal amounts of 
fat, protein and starch on plasma CCK is presented. Cholinergic 
control of CCK release is the subject of chapter III, in which 
the effect of atropine on CCK release after intraduodenal instil­
lation of corn oil has been investigated. Further data on neural 
control of CCK release are presented in chapter IV dealing with 
CCK release in patients with truncal vagotomy, highly selective 
vagotomy and duodenal ulcer. The question as to whether bypassing 
the duodenum affects CCK release in patients with a Billroth II 
gastrectomy following oral ingestion of a liquid fat meal is 
answered in chapter V. 
A computerized method for rapid quantification of gallbladder 
volumes from real-time sonograms is introduced in chapter VI. In 
chapter VII real-time ultrasonography as a method to quantitate 
gallbladder contraction is compared to intraduodenal bilirubin 
output, another method to assess gallbladder emptying in man. 
Using ultrasonography to determine gallbladder contraction, the 
role of CCK in control of gallbladder motility is investigated. 
The question whether physiological plasma CCK levels can stimu­
late gallbladder contraction is answered in chapter VII. In this 
chapter the effect of graded doses of exogenous CCK resulting in 
plasma CCK levels not exceeding those found after a meal on gall­
bladder contraction is studied. Chapter VIII and IX are dealing 
with the effect of different nutrients on CCK release and gall­
bladder motility. In chapter VIII the effect of equimolar amounts 
of long-chain triglycerides and medium-chain triglycerides after 
oral ingestion on plasma CCK and gallbladder contraction is com­
pared. Chapter IX reports on the effect of oral ingestion of an 
elemental diet on plasma concentrations of CCK and PP with simul-
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taneous recording of gallbladder volume. Finally, in chapter X 
the effects of two commercially available fatty meals and 
intravenous cholecystokimn on gallbladder contraction and on 
plasma levels of CCK and PP is studied. 
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Abstract 
The effect of ingestion of 50 g fat, 50 g protein and 50 g 
starch on plasma cholecystokinin (CCK) concentrations was studied 
in θ healthy volunteers. Plasma CCK concentrations were measured 
by radioimmunoassay employing Bolton-Hunter labelled CCK 33, CCK 
standard and antibody Т20Ч. Antibody Ί204 was directed to the 
sulphated tyrosine region of CCK. Ingestion of fat and protein 
induced significant increases in plasma CCK, while ingestion of 
starch did not significantly influence plasma CCK levels. Peak 
increments in plasma CCK after fat (4.8 ± 0.9 pmol/1 and protein 
(3.4 ± 0.5 pmol/1) were significantly greater than that after 
starch (0.9 ± 0.3 pmol/1). Similarly, the integrated plasma CCK 
secretion after fat (213 * 19 pmol/1'120 min) and after protein 
(178 ± 53 pmol/1-120 min) were significantly greater than that 
found after ingestion of starch (9 ± 23 pmol/l*120 min). It is 
concluded that, in contrast to starch, fat and protein are potent 
stimuli for the release of CCK. 
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Introduction 
In the absence of reliable radioimmunoassays for cholecystoki-
nin (CCK) pancreatic enzyme secretion was used for many years as 
bioassay system to monitor the secretion of CCK into plasma (1). 
Based on studies of pancreatic enzyme secretion it was suggested 
that fat and protein products were potent stimuli for the secre-
tion of CCK, while carbohydrates were ineffective in stimulating 
the release of CCK (1-8). Recently several radioimmunoassays for 
measurement of CCK in human plasma have been developed (9-18). 
Using these assays it has been shown that ingestion of fat 
(10,11,12,14,15,17) or a mixed meal (9,12,13 f 1 5 , 1 6 , 18 ) induces 
significant increases in plasma CCK in man. However, no compara-
tive studies on the relative potencies of pure nutrients to sti-
mulate CCK secretion have been performed. Using a recently deve-
loped specific and sensitive radioimmunoassay for CCK (17,19), we 
have compared the effects of equal amounts of fat, protein and 
starch on plasma CCK concentrations m normal subjects. 
Subjects and methods 
Eight healthy volunteers (7 male, 1 female; mean age 33 years, 
range 21-60 years) participated in the study. On separate mor-
nings after an overnight fast 3 meals were ingested . The meals 
consisted of 250 ml 20Í Intralipid (Kabi Vitrum, Stockholm, Swe-
den) containing 50 g soybean oil, 57 g Proteine 88 (Wander, Uden, 
The Netherlands) containing 50 g mille protein solubilized in wa-
ter to a volume of 250 ml, and 50 g starch also solubilized in 
water to a volume of 250 ml. The meals were ingested within 10 
minutes. Blood samples for measurement of CCK were obtained at 
-5, 0, 10, 20, 30, 40, 50, 60, 75, 90, 105 and 120 minutes. 
Plasma CCK concentrations were measured by a sensitive and 
specific radioimmunoassay (17,19). The antibody used (Τ20Ό bound 
to all CCK-peptides containing both the sulphated tyrosine region 
and the carboxylterminus of CCK (figure 1). The antibody did not 
significantly bind to synthetic araino-terminal CCK-peptides (CCK 
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Figure 1 Standard curve of antibody T204 using CCK 33 coupled to 
125i_hydroxyphenylpropionic acid-succiniraide-ester аз 
label. For further data see text. 
1-15, CCK 1-21), mid-fragments (CCK 10-20, CCK 16-27), 
earboxyl-terminal CCK-peptides devoid of the sulphated tyrosine 
region (unsulphated CCK 8, CCK Ц) or to structurally unrelated 
regulatory peptides including insulin, glucagon, somatostatin, 
pancreatic polypeptide, secretin, gastric inhibitory polypeptide, 
vasoactive intestinal polypeptide, bombesin and neurotensin. In 
addition, the antibody did not bind to unsulphated gastrin 17 and 
gastrin 34, while the crossreactivity with sulphated gastrins was 
negligible (about 2%). 99% Pure porcine CCK 33 (V. Mutt, 
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Results were expressed as the mean ± 1 SEM. Integrated CCK se­
cretion was determined by calculating the area under the curve 
after subtraction of the basal value. Statistical analysis was 
done by Student's t-test for paired results. Informed consent was 
obtained from all subjects studied. 
Results 
Ingestion of both fat and protein induced significant increas­
es In plasma CCK concentrations, whereas starch did not signifi­
cantly influence plasma CCK levels (figure 2). Plasma CCK concen­
trations were significantly (p < 0.0005 - ρ < 0.05) increased 
over basal value at 10, 20, 30, 40, 50, 60, 75 and 90 minutes af­
ter ingestion of fat and in all samples after ingestion of pro­
tein. At 20,30,40, 50 and 60 minutes after ingestion of fat (p< 
0.005 - ρ < 0.05) and at 10, 50, 60, 90 and 105 minutes after 
protein (p < 0.005 - Ρ < 0.05) plasma CCK concentrations were 
significantly greater than those found after ingestion of 
starch. Peak increments of plasma CCK after fat (4.8 * 0.9 
praol/1) and protein (3.4 ± 0.5 pmol/1) were significantly greater 
than that found after ingestion of starch (p < 0.001 and ρ < 
0.005, respectively). Similarly the integrated plasma CCK 
secretion after fat (213 ± 49 pmol/1· 120 min) and after protein 
(178 ± 53 pmol/1'120 m m ) were significantly greater than after 
ingestion of starch (9 ± 23 pmol/1'120 rain.; ρ < 0.01 and p< 
0.05, respectively; figure 3). There were no significant 
differences in the plasma CCK responses to fat and to protein. 
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Figure 2 The effect of 50 g fat (closed circles), 50 g protein 
(open circles) and 50 g starch (triangles) on plasma 
cholecystokinin concentrations in θ normal subjects. 
Dicussion 
It has generally been accepted that CCK plays a role in the 
stimulation of gallbladder contraction and pancreatic enzyme se­
cretion after feeding (21). In the absence of reliable radioimmu­
noassays for CCK, pancreatic enzyme secretion has been used for 
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many years as a bioassay system to monitor plasma CCK secretion 
(1). However, it has recently been demonstrated that the pancrea­
tic enzyme response to food is not a reliable measure for the se­
cretion of CCK into the circulation, because nutrients are able 
to stimulate pancreatic enzyme secretion by a duodenopancreatic 
reflex mechanism (22-24). 
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Figure 3 Integrated plasma CCK secretion after ingestion of 50 g 
fat, 50 g protein and 50 starch in 8 normal subjects 
Recently several groups have succeeded in developing radioim­
munoassays for CCK sufficiently sensitive to measure CCK in human 
plasma (9-18). The introduction of a non-oxidizing labelling 
method, as used in the present study, has contributed considera­
bly to the development of the CCK-assay (20). In some assays CCK 
was separated from gastrin by column chromatography (13,15) or 
33 
high pressure liquid chromatography (14) and subsequently measur­
ed using an antibody fullly cross-reacting with gastrin. In other 
assays more or less specific CCK-antibodies were employed (9-12, 
Іб-ΐθ). Some antibodies bound to both large and small forms of 
CCK (9,10,12-17), whereas other antibodies bound to large forms 
only (11,17). The antibody used in the present study binds to all 
CCK-peptides containing both the sulphated tyrosine region and 
the carboxy1-terminus (17,19). Since both the carboxyl-terramus 
and the sulphated tyrosine region are required for biological ac­
tivity, it can be concluded that the antibody recognizes 
biologically active forms of CCK. 
Several groups have shown that ingestion of fat or a mixed 
meal induces significant increases in plasma CCK (9-18). However, 
no studies have been performed comparing the relative potencies 
of pure nutrients to release CCK from the small intestine in 
man. In the present study we have shown that both fat and protein 
are effective stimuli for the secretion of CCK, while starch is 
Ineffective in influencing plasma CCK concentrations. Equal 
amounts of pure nutrients solubilized in the same volume of water 
were ingested by the healthy volunteers. Although CCK-secretion 
was greater after ingestion of fat than after protein, the dif­
ference did not reach statistical significance. 
The results obtained in this study by measurement of plasma 
CCK by radioimmunoassay confirm previous studies in which pan­
creatic enzyme secretion was used as a bioassay system to monitor 
CCK secretion. In dogs with a subcutaneously autotransplanted 
pancreas it was shown that pancreatic enzyme secretion was stimu­
lated by intraduodenal instillation of corn oil, sodium oleate, 
amino acids and peptone, whereas starch, maltose and dextrose 
were ineffective in stimulating pancreatic enzyme secretion (2). 
Similarly, Meyer et al showed that in dogs with pancreatic fistu­
las long-chain fatty acids and protein digestion products stimu­
lated pancreatic protein secretion (3-5). Also in man it has been 
shown that products of fat digestion, such as micellar solutions 
of monooleine, oleic acid and lauric acid, and products of pro­
tein digestion stimulated pancreatic enzyme secretion and gall­
bladder contraction during intestinal perfusion (1,6,7,8). Perfu-
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зіоп of the intestine with dextrose, isotonic saline or glycerol 
did not elicit pancreatic enzyme secretion or gallbladder con­
traction in man (1,7,8). 
It is concluded that, m contrast to starch, fat and protein 
are potent stimuli of the secretion of CCK. These findings combi­
ned with previous bioassay studies (1-8) suggest that CCK releas­
ed into plasma after ingestion of fat or protein may play a role 
in the stimulation of pancreatic enzyme secretion and gallbladder 
contraction in man. 
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Abstract. The present study was undertaken to determine whether atropine inhibits the 
plasma cholecystokinin (CCK) response to intraduodenal fat. Plasma CCK. concentrations 
were measured by radioimmunoassay using two sequence-specific antibodies. Antibody 1703 
bound to all COOH-terminal CCK peptides containing at least 14 amino acid residues, while 
antibody T204 was specific for the sulphated tyrosine region of CCK. Intraduodenal instilla-
tion of 60 ml corn oil in 6 normal subjects induced significant increases in plasma CCK. 
Intravenous administration of atropine (0.015 mg/kg as bolus followed by 0.005 mg/kg · h 
over 3 h) resulted in significant inhibition of plasma CCK concentrations at 10, 20 and 30 min 
(antibody 1703) and at 20 and 30 min (antibody T204) after instillation of fat. However, the 
peak increments in plasma CCK during atropine (8.6 ± 1.9 pmol/1, antibody 1703; 5.4 ±1.1 
pmol/1, antibody T204) were not different from those found without atropine (6.3 ± 0.8 
pmol/1, antibody 1703; 3.9 ± 0.9 pmol/1, antibody T204). Similarly, the integrated plasma 
CCK secretion after intraduodenal fat was not significantly different when measured during 
atropine (461 ± 119 pmol/1 · 3 h, antibody 1703; 269 ± 97 pmol/1 · 3 h, antibody T204) and 
without atropine (428 ± 62 pmol/1 • 3 h, antibody 1703; 188 ± 66 pmol/1 · 3 h). 
It is concluded that administration of atropine delays but does not inhibit the CCK 
response to intraduodenal com oil in man. 
Intraduodenal instillation of fat increases 
both plasma cholecystokinin (CCK) concen-
trations and pancreatic enzyme secretion in 
man [1]. Administration of atropine inhibits 
1
 ' Supported by the Foundation for Medical Re-
search FUNGO (grant No. 13-37-32). 
the pancreatic enzyme response to intraduo-
denal nutrients [2-5]. It is not known 
whether this inhibition of pancreatic enzyme 
secretion by atropine results from an im-
paired CCK response to intradupdenal fat. 
In the present study we have measured the 
effect of atropine on plasma CCK secretion 
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stimulated by intraduodenal administration 
of com oil. Plasma CCK concentrations were 
measured by two sequence-specific radioim­
munoassays [1, 6]. Antibody 1703 binds to 
all COOH-terminal CCK peptides containing 
at least 14 amino acid residues, while anti­
body T204 is specific for the sulphated tyro­
sine region in CCK. 
Subjects and Methods 
6 healthy male volunteers, aged 21-25 years, were 
studied. After an overnight fast the tip of a single-
lumen tube was placed under fluoroscopic control into 
the second part of the duodenum. On separate morn­
ings and in random order the effect of intraduodenal 
instillation of fat on plasma CCK concentrations was 
studied with and without administration of atropine. 
In the control study 60 ml of com oil was instilled into 
the duodenum within 10 mm and blood samples for 
Table I. Relative binding of CCK peptides and 
gastrins to antibody 1703 and antibody T204 
CCK39 
CCK33 
CCK20-33 
CCK22-33 
CCK24-33 
CCK26-33 
CCK26-33 
CCK30-33 
CCK 1-21 
CCK1-15 
CCK 10-20 
CCK 16-27 
CCK20-27 
sulphated 
unsulphated 
Gastrin 34 sulphated 
Gastrin 34 
Gastrin 17 
unsulphated 
sulphated 
Gastrin 17 unsulphated 
Antibody 
1703 
0.91 
1.00 
0.62 
< 0 . 0 1 
< 0 . 0 1 
< 0 . 0 1 
< 0 . 0 1 
< 0 . 0 1 
< 0 . 0 1 
< 0 . 0 1 
< 0 . 0 1 
0 0 1 
0.01 
< 0 . 0 1 
< 0 . 0 1 
< 0 0 1 
< 0 . 0 1 
Antibody 
T204 
1.09 
1.00 
1.69 
1.71 
0.78 
0.65 
< 0 . 0 1 
<0.01 
<0.01 
< 0 . 0 1 
<0.01 
0.01 
0.02 
0.02 
< 0 . 0 1 
0.02 
< 0 . 0 1 
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CCK were obtained in ice-chilled tubes containing 
ethylenediaminetetraacetate at -5, 0, 10, 20, 30, 40, 
50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165 and 
180 min. In the atropine study a bolus of 0.015 mg/kg 
atropine was administered at -15 mm followed by 
infusion of 0.005 mg/kg h atropine over 3 h. Blood 
samples were drawn at-20, -15, -5, 0, 10, 20, 30, 40, 
50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165 and 
180min. Before and during administration of atro­
pine the pulse rate was counted at regular intervals. 
Plasma CCK concentrations were measured by ra­
dioimmunoassay usrng two antibodies with different 
specificities [1,6]. Antibody 1703 binds to all COOH-
lerminal CCK peptides containing at least 14 amino 
acid residues and does nol show any cross-reactivity 
with gastrin (table 1). Antibody T204 binds to all CCK 
peptides containing the sulphated tyrosine region. 
This antibody shows low binding to sulphated gastrins 
but it does not bind to unsulphated gastrins (table I). 
The antibodies do not bind to structurally unre­
lated regulatory peptides, including insulin, glucagon, 
pancreatic polypeptide, somatostatin, secretin, gastric 
inhibitory polypeptide, vasoactive intestinal polypep­
tide, bombesin or neurotensin. Measurement of the 
eluate of a Sephadex G-50 column to which an 
aqueous-acid extract of human upper small intestine 
was applied showed that both antibodies bind to com­
ponent I CCK, CCK33-CCK39, and intermediate 
CCK, while antibody T204 binds also to CCK8 [1]. 
CCK33 coupled to 125I-hydroxyphenylpropionic acid 
succinimide ester (Bolton Hunter reagent) was used as 
label [7]. 99% pure porcine CCK33 was used as stan­
dard. 0.05 mol/1 sodium phosphate buffer pH 7.4 con­
taining 0.08 mmol 1 human scrum albumin and 0.06 
mmol/1 sodium elhylmercunthiosalicylate was used as 
assay buffer. A non-equihbnum system was used with 
72 h preincubation followed by 24 h incubation after 
addition of the labelled peptide. Separation between 
free and antibody-bound hormone was performed by 
adsorption of the free peptide to plasma-coated char­
coal. The 50% inhibition dose (ID50) was 2.8 pmol/1 
for antibody 1703 and 3.3 pmol/1 for antibody T204. 
Plasma samples were extracted in 96% ethanol, dned 
under nitrogen at 37°С and reconstituted in assay 
bufler to the original volume before the assay. Recov­
ery of CCK33 and sulphated CCK8 added to hor­
mone-free plasma was 85.4 ± 2.0% (n = 11) and 89.8 
± 1.7% (n = 7), respectively. The detection limit of 
both assays was about 0.5 pmol/1 plasma. The intra-
assay variation was 11.5% at 1.2 pmol/1, 8.4% at 2.5 
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pmol/1 and 4.6% at 8.0 pmol/1 CCK. The tnter-assay 
variation was 26.1% at 1.3 pmol/1, 11.3% at 2.6 
pmol/1 and 15.4% at 8.8 pmol/1 CCK. Dilution curves 
of plasma samples containing a high concentration of 
endogenous CCK were parallel to the standard 
curve. 
Results were expressed as the mean ± 1 SEM. The 
integrated plasma CCK secretion after intraduodenal 
instillation of fat was determined by calculating the 
area under the curve after subtraction of the basal val­
ue. When CCK concentrations were below the basal 
value, the results were subtracted. Statistical analysis 
was done by Student's l test for paired results. In­
formed consent was obtained from all subjects stud­
ied. 
Results 
Intraduodenal instillation of com oil in­
duced significant increases in plasma CCK. 
Plasma CCK concentrations at 10, 20, 30, 
40, 50, 60, 70, 80, 90, 100, 110, 120 and 
135 min were significantly (p < 0.005-0.05) 
increased over basal value when measured 
with antibody 1703, and at 20, 30, 40, 50, 60, 
70, 80 and 90 min (ρ < 0.05) when measured 
with antibody T204 (fig. 1). Administration 
of atropine did not significantly change the 
basal plasma CCK concentration. Basal 
plasma CCK concentrations before adminis­
tration of atropine were 1.5 ± 0.4 pmol/1 
(antibody 1703) and 3.0 ± 0.5 pmol/1 (anti­
body T204), while plasma CCK levels during 
atropine were 1.0 ± 0.1 pmol/1 (antibody 
1703) and 2.5 ± 0.6 pmol/1 (antibody T204). 
During administration of atropine, plasma 
CCK concentrations after intraduodenal in­
stillation of fat were significantly (p < 0.001-
0.05) greater than basal value at 70, 80, 90, 
100, 110, 120, 135, 150 and 165 min when 
measured with antibody 1703, and at 40, 60, 
70, 80, 90, 100, 120, 135, 150, 165 and 
180 min (ρ < 0.005-0.05) when measured 
with antibody T204. Plasma CCK concentra­
tions during atropine were significantly lower 
(p < 0.05) than those without atropine at 10, 
20 and 30 min when measured with antibody 
1703, and at 20 and 30 min when measured 
with antibody T204. However, the peak 
increment in plasma CCK during atropine 
(8.6 ± 1.9 pmol/1, antibody 1703; 5.4 ± 1.1 
pmol/1, antibody T204) was not significantly 
different from that without atropine (6.3 ± 
0.8 pmol/1, antibody 1703; 3.9 ± 0.9 pmol/1, 
antibody T204). Similarly, the integrated 
plasma CCK secretion during atropine (461 
± 119 pmol/1 · 3 h, antibody 1703; 269 ± 97 
pmol/1 · 3 h, antibody T204) did not signifi­
cantly differ from that without atropine (428 
± 62 pmol/1 · 3 h, antibody 1703; 188 ± 66 
pmol/1 · 3 h, antibody T204). Figure 2 shows 
the integrated plasma CCK secretion, mea­
sured in 30-min periods, in response to intra­
duodenal instillation of fat. Significant differ­
ences between CCK secretion with and with­
out atropine were observed only in the first 
30-min period (p < 0.01, antibody 1703 and 
ρ < 0.05, antibody T204). 
Administration of atropine induced sig­
nificant (p < 0.01) increases in pulse rate 
during the whole study (fig. 3). Furthermore, 
all subjects complained of a dry mouth dur­
ing and at least 30 min after administration 
of atropine. 
Discussion 
The present study showed that intraduo­
denal instillation of fat induced significant 
increases in plasma CCK in man. Adminis­
tration of atropine resulted in a delay in the 
plasma CCK response to intraduodenal fat. 
The plasma CCK secretion during the first 
30 min after instillation of com oil was sig­
nificantly inhibited by atropine. However, 
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Kif 
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Time (min) 
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150 180 
Time (mmj 
Fig. 1. Effect of atropine on 
plasma CCK concentrations after 
intraduodenal instillation of fat. 
The closed circles denote plasma 
CCK concentrations during admin-
istration of atropine and open cir-
cles those without atropine. Results 
obtained with antibody 1703 are 
shown in the upper panel and those 
with antibody T204 in the lower pa-
nel. Astensks indicate significant 
differences between the results with 
and without atropine. 
the total integrated plasma CCK release over 
3 h was not significantly influenced by ad-
ministration of atropine. In fact, there was a 
tendency to increased plasma CCK concen-
trations during atropine in the 3rd hour after 
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instillation of fat. The mechanism by which 
atropine delays the plasma CCK response to 
intraduodenal com oil is unknown. It has 
been reported that in dogs triglycerides do 
not stimulate pancreatic enzyme secretion 
EfTecl of Atropine on CCK. 
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Fig. 2. Effect of atropine on integrated plasma CCK secretion in response to intraduodenal fat. The solid bars 
represent results without and the striped bars with atropine. Results obtained: a with antibody 1703; b with 
antibody T204. 
Fig. 3. Effect of administration 
of atropine on pulse rate. 
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unless conditions are met which favour lipo- per small intestine. It is likely that adminis-
lysis [8]. If this finding is extrapolated to tration of atropine affects luminal conditions 
man, it suggests that luminal triglycerides for lipolysis. It is, however, hard to see why 
need to be converted into free fatty acids in large amounts of CCK are released later in 
order to stimulate CCK release from the up- the study during adequate atropinization. An 
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alternative explanation for the delay in the 
plasma CCK response to corn oil during atro-
pine is the effect of atropine on small intesti-
nal motility. Inhibition of small intestinal 
motility by atropine may affect the contact 
between corn oil and the upper small intesti-
nal mucosa containing the CCK-producing 
cells. 
The absence of inhibition by atropine of 
CCK secretion in response to intraduodenal 
nutrients has previously been suggested 
based upon the lack of inhibition by atropine 
of enzyme secretion from the transplanted 
pancreas [4, 5]. An enteropancreatic reflex 
mechanism for pancreatic enzyme secretion 
has been proposed partly based on the as-
sumption that atropine does not inhibit the 
plasma CCK response to intraduodenal nu-
trients [4, 5] This assumption is substan-
tiated in the present study using sequence-
specific radioimmunoassays for CCK 
In two recent studies, reported m abstract 
form, the effect of atropine on fat-stimulated 
plasma CCK secretion was measured by ra-
dioimmunoassay [9, 10] Maton et al. [9] 
showed that administration of atropine in-
hibited the plasma CCK response to oral fat. 
Since the dose of atropine used is known to 
inhibit gastric emptying [11], it is impossible 
to conclude whether this impaired CCK re-
lease results from a direct inhibition of CCK 
secretion by atropine or from a reduced intra-
duodenal load of fat due to slow gastric 
emptying. Lilja et al [10] reported that ad-
ministration of atropine inhibited the plasma 
CCK response to intraduodenal com oil in 
dogs. Since these workers measured the 
plasma CCK concentrations for only 60 mm, 
it cannot be derived from that study whether 
atropine inhibited or delayed the plasma 
CCK response to intraduodenal fat. 
There is considerable controversy related 
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to the molecular forms of CCK in plasma In 
the present study intraduodenal instillation 
of com oil induced significant increases in 
plasma CCK as measured with two anti-
bodies. Since antibody 1703 binds to COOH-
terminal CCK peptides containing at least 14 
amino acid residues, it can be concluded that 
large or intermediate forms of CCK are 
present in plasma after intraduodenal com 
oil Measurement with antibody T204 indi-
cates that sulphated forms of CCK are re-
leased after com oil We have recently shown 
that several molecular forms of CCK, both 
larger and smaller than CCK33, are released 
during infusion of bombesin in man [12]. 
Studies using radioimmunoassay techniques 
employing gastrin antibodies with different 
degrees of cross-reactivity with CCK have 
suggested that a small molecular form of 
CCK, possibly CCK8, predominates in post-
prandial plasma [13-15] However, radioim-
munoassays using more specific CCK anti-
bodies or other separation techniques indi-
cate that considerable amounts of larger 
forms of CCK are released after feeding [ 16-
19] In this respect it is interesting to note 
that after feeding in dogs small CCK predom-
inates in portal blood, while large forms of 
CCK predominate in peripheral plasma [20]. 
In another study by the same group it was 
shown that the different ratios between large 
and small forms of CCK in portal and pe-
ripheral plasma resulted from a preferential 
elimination of small forms by passage 
through the liver [21]. 
In conclusion, administration of atropine 
delays, but does not inhibit the plasma CCK 
response to intraduodenal com oil in man. 
This finding should be taken into account 
when interpreting studies on the effect of 
atropine on pancreatic enzyme secretion in 
response to intraduodenal fat. 
Eflecl of Atropine on CCK. 
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CHAPTER IV 
PLASMA CHOLECYSTOKININ RESPONSE TO A LIQUID FAT MEAL IN VAGO-
TOMIZED PATIENTS 
Wim P.M. Hopman, Jan B.M.J. Jansen, Cornells B.H.W. Lamers 
Ann Surg: accepted for publication. 
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Abstract 
Since previous studies have suggested that in patients with 
truncal vagotomy the plasma cholecystokinin (CCK) secretion in 
response to nutrients is impaired, we have measured the plasma 
CCK response to a liquid fat meal (250 ml 20% Intralipid) in 6 
patients with truncal vagotomy and pyloroplasty and we have com­
pared the results with those obtained in 8 normal subjects, 6 pa­
tients with duodenal ulcer and 8 patients with highly selective 
vagotomy. Plasma CCK concentrations were measured by a sensitive 
and specific radioimmunoassay employing antibody ТЗО1! directed 
against the sulphated tyrosine region of CCK. Basal plasma CCK 
concentrations were not significantly different among the ll 
groups studied (2.1 ± o.M pmol/1 in normal subjects, 2.8 ± 0.5 
pmol/1 in duodenal ulcer patients, 3.1 * 0.5 pmol/1 in patients 
with truncal vagotomy and 2.7 ± 0.5 pmol/1 in patients with high­
ly selective vagotomy). The increments in plasma CCK after inges­
tion of the fat meal in patients with truncal vagotomy (15.7 * 
3.1 pmol/1) and highly selective vagotomy (14.9 ± 1.6 pmol/1) we­
re significantly higher (p < 0.01) than those in normal subjects 
(Ц.8 ± 0.9 pmol/1) and in patients with duodenal ulcer (5.5 ± 0.6 
pmol/1). Similarly, the integrated plasma CCK secretions in pa­
tients with truncal vagotomy (551 * 139 pmol/1-120 min) and in 
patients with highly selective vagotomy (876 ± 132 praol/1-120 
rain) were significantly increased (p < 0.05) compared to those in 
normal subjects (187 * 29 pmol/1'120 min) and in patients with 
duodenal ulcer (264 ± 35 pmol/l*120 rain). 
It is concluded that patients with truncal vagotomy and highly 
selective vagotomy show an increased plasma CCK secretion in res­
ponse to a liquid test meal . 
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Introduction 
Previous studies have shown that in patients with truncal va­
gotomy the pancreatic enzyme secretion in response to nutrients 
is impaired (1-3). Since the pancreatic enzyme response to exoge­
nous hormonal stimulants was not impaired, it was postulated that 
vagotomy reduced the amount of cholecystokinin (CCK) released 
from the small intestinal mucosa in response to feeding (1-5). In 
the absence of reliable radioimmunoassays for CCK in plasma this 
suggestion could neither be confirmed nor rejected. 
We have recently developed a specific radioimmunoassay for CCK 
sufficiently sensitive to measure the low plasma CCK concentra­
tions in human plasma (6,7). Using this radioimmunoassay we have 
measured the plasma CCK response to a liquid fat meal in patients 
with truncal vagotomy and we have compared the results with those 
obtained in normal subjects, in patients with duodenal ulcer and 
in patients with highly selective vagotomy. 
Patients and Methods 
Six patients with truncal vagotomy and pyloroplasty (5 male, 1 
female, mean age 49 years, range 27 - 65 years), 8 patients with 
highly selective vagotomy (7 male, 1 female, mean age 36 years, 
range 26 - 51 years), 6 patients with duodenal ulcer (H male, 2 
female, mean age 44 years, range 23 - 70 years) and θ normal sub­
jects (7 male, 1 female, mean age 33 years, range 21 - 60 years) 
were studied. 
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Figure 1 Binding of CCK-peptides to antibody 1201 using CCK 33 
coupled to 125l-hydroxyphenylpropionic acid succinimide 
ester (Bolton Hunter reagent) as label. 
CCK 1-21), mid-fragments (CCK 10-20, CCK 16-27) or carboxyl-ter-
minal CCK-peptides devoid of the sulphated tyrosine region (un-
sulphated CCK 8, CCK 4). The antibody did not bind to unsulphated 
gastrin 17 and gastrin 3H, while the cross-reactivity with sul­
phated gastrins was negligible (about 2%). Furthermore, there was 
no binding to structurally unrelated regulatory peptides inclu­
ding insulin, glucagon, somatostatin, pancreatic polypeptide, se­
cretin, gastric inhibitory polypeptide, vasoactive intestinal 
polypeptide, bombesin, gastrin releasing peptide and neuroten­
sin. 99% Pure porcine CCK 33 (V. Mutt, Karolinska Institute, 
Stockholm, Sweden) coupled to 125l-hydroxyphenyIpropionic acid-
50 
succinimide ester ( Bol ton-Hunter reagent, New England Nuclear, 
Boston, MA, USA) was used as label and 99$ pure porcine CCK was 
used as standard preparation. The concentration of CCK 33 displa-
cing 50Í of the label from the antibody (inhibition dose 50, ID 
50) was 3.3 pmol/1 incubation mixture. Plasma samples were ex-
tracted using 96Í ethanol. A non-equilibrium system was used with 
72 hours preincubation followed by 24 hours incubation after ad-
dition of the labeled peptide. The detection limit of the assay 
was between 0.5 and 1.0pmol/l plasma. Using this assay it was 
shown that CCK in plasma is heterogeneous and that antibody Т20Д 
recognizes all molecular forms of CCK detected by a carboxyl-ter­
minal CCK/gastrin antibody (7). The intra-assay variation was 
11.5$ at 1.2 pmol/1, 8,456 at 2.5 pmol/1 and 4.6ÎÉ at 8.0 pmol/1 
(n=5). The interassay variation was 26.1Ï at I.3 pmol/1, 11.3$ at 
2.6 pmol/1 and 15.4% at 8.8 pmol/1 (n=5). 
Results were expressed as the mean ± 1 SEM. Integrated CCK-se-
cretion was determined by calculating the area under the curve 
after subtraction of the basal value. Statistical analysis was 
done by Student's t-test for paired and unpaired results. Inform-
ed consent was obtained from all subjects studied. 
Results 
Basal plasma CCK concentrations were not significantly dif-
ferent in the Ц groups of subjects studied (2.1 ± 0.4 pmol/1 in 
normal subjects, 2.8 * 0.5 pmol/1 in patients with duodenal ul­
cer, 3.1 ± 0.5 pmol/1 in patients with truncal vagotomy and 2.7 ± 
0.5 pmol/1 in patients with highly selective vagotomy). Ingestion 
of 250 ml 20? Intralipid induced increases in plasma CCK in all 
subjects studied (fig. 2 and 3). In normal subjects plasma CCK 
concentrations at 10, 20, 30, 40, 50, 60, 75 and 90 minutes were 
significantly increased over basal (p < 0.05 - ρ < 0.0005), in 
duodenal ulcer patients all postprandial CCK concentrations were 
significantly higher than basal value (p < 0.05 - ρ < 0.001), in 
patients with truncal vagotomy and pyloroplasty plasma CCK levels 
at 20, 30, 40 and 60 minutes were significantly increased over 
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basal value (ρ < 0.05 - Ρ < 0.005), and in patients with highly 
selective vagotomy plasma CCK concentrations at 10, 20, 30, 40, 
50, 60, 75, 90 and 105 minutes were significantly higher than ba­
sal value (p < 0.05 - Ρ < 0.0005). Apart from the CCK concentra­
tion at 75 min (ρ < 0.005), plasma CCK concentrations in normal 
subjects and patients with duodenal ulcer were not significantly 
different (fig. 2). 
As shown in figure 3, in patients with truncal vagotomy plasma 
Plasma CCK -
(pmol/l ) 
10-, 250ml 
20 '/.Intralipid 
30 60 90 120 
Time (mm ) 
Figure 2 Plasma CCK concentrations in response to a liquid fat 
meal (250 ml 20Í Intralipid) in 6 patients with duode-
nal ulcer (closed circles) and in 8 normal subjects 
(open circles). The asterisk denotes a significant dif-
ference from the normal subjects (p < 0.05). 
CCK concentrations at 20, 30 and Ц0 minutes and in patients with 
highly selective vagotomy those obtained at 10, 20, 30, 40, 50, 
60, 75 and 105 minutes were significantly elevated over the con­
centrations in the normal subjects (p < 0.005 - Ρ < 0.0005). 
Apart from the concentration at 60 minutes (p = 0.04) plasma CCK 
concentrations in patients with truncal vagotomy and highly se­
lective vagotomy were not significantly different. The increments 
in plasma CCK in patients with truncal vagotomy (15.7 * 3-1 
pmol/l) and in patients with highly selective vagotomy (14.9 * 
1.6 pmol/l) were significantly higher than those in normal sub-
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Figure 3 Plasma CCK concentrations in response to a liquid fat 
meal (250 ml 20% Intralipid) in 6 patients with truncal 
vagotomy and pyloroplasty (triangles), in 8 patients 
with highly selective vagotomy (closed circles) and in 8 
normal subjects (open circles). Asterisks denote signi­
ficant differences from the normal subjects (p < 0.005 -
ρ < 0.0005) . 
jects (4.8 ± 0.9 praol/1; ρ < 0.005 and ρ = 0.0001) and in pa-
patients with duodenal ulcer (5.5 ± 0.6 pmol/l; ρ < 0.01 and ρ = 
0.0005). The increments in both groups of vagotoraized patients 
were not significantly different from each other. Also, the in­
crements in plasma CCK in patients with duodenal ulcer and normal 
patients did not significantly differ. 
The integrated plasma CCK secretions over 120 minutes in pa­
tients with truncal vagotomy (554 ± 139 pmol/1'120 min) and 
highly selective vagotomy (876 ± 132 pmol/l-i20 min) were sig-
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nificantly increased over that in normal subjects (187 ± 29 
praol/1-120 rain; ρ = 0.01 and ρ < 0.0005, respect ivily) , whereas 
the integrated plasma CCK secretion in patients with duodenal ul­
cer (264 ± 3U pmol/1'120 m m ) did not significantly differ from 
that in the normal subjects (fig. Ό . The integrated plasma CCK 
secretion in both groups of vagotomized patients did not signifi­
cantly differ from each other. As shown in figure 5 the differen­
ces between the groups over 2 hours were almost exclusively due 
to differences in the first hour after ingestion of the meal. The 
integrated plasma CCK secretions over 60 minutes in patients with 
truncal vagotomy (492 ± 118 pmol/l'60 min) and highly selective 
vagotomy (560 ± 60 pmol/1-60 min) were significantly increased 
over that in the normal subjects (140 ± 22 pmol/1. 60 min; ρ = 
0.005 and ρ < 0.0001, respectively). Again, there was no statis­
tically significant difference between patients with truncal va­
gotomy and highly selective vagotomy. Furthermore, the integrated 
plasma CCK secretion in patients with duodenal ulcer (185 * 23 
praol/1'60 m m ) did not significantly differ from that in the 
normal subjects. 
Discussion 
In the absence of reliable radioimmunoassays for CCK, pancrea­
tic enzyme secretion was used as a bioassay system to monitor CCK 
secretion from the upper small intestine (8). Using this bioassay 
system it was shown that in patients with truncal vagotomy pan­
creatic enzyme secretion during perfusion of the small intestine 
with amino acids was impaired (1,2). An impaired pancreatic en­
zyme secretion in patients with truncal vagotomy was also observ­
ed after ingestion of a liquid test meal (3) and in vagotomized 
dogs after various intestinal stimuli (4,5,9). Since the pancreas 
responded normally to exogenous hormonal stimulation, it was sug­
gested that after truncal vagotomy the CCK secretion in response 
to nutrients was reduced (1-4). However, in later studies in dogs 
with a transplanted pancreas it was indirectly shown that vago­
tomy did not affect CCK secretion in response to nutrients (10). 
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In a recent study, using a radioimmunoassay for large molecular 
forms of CCK, Fried and co-workers found that in dogs truncal 
vagotomy did not reduce CCK secretion in response to 
intraduodenal oleate (9)· 
Integrated plasma CCK 
( n m o l / M 2 0 n n i n ) 
1.2 
0 8 -
0Д 
normal duodenal highly truncal 
subjects ulcer selective vagotomy 
vagotomy (n = 8) (n=6) (n=8) (n = 6) 
Figure 4 Integrated plasma CCK secretion in response to a liquid 
fat meal (250 ml 20% Intralipid) over 2 hours in 8 nor­
mal subjects, 6 patients with duodenal ulcer, in 8 pa­
tients with highly selective vagotomy and in 6 patients 
with truncal vagotomy. 
In the present study we have measured plasma CCK responses to 
a liquid fat meal in patients with truncal vagotomy and we have 
compared the results with those obtained in normal subjects, in 
patients with duodenal ulcer and in patients with highly selec­
tive vagotomy. Plasma CCK was measured by a sensitive and speci­
fic radioimmunoassay (6,7). The antibody used bound to all CCK-
peptides containing the sulphated tyrosine region and the car-
boxyl-terminus of CCK. Since both the sulphated tyrosine region 
and the carboxyl-terminus are required for biological activity of 
CCK, it can be concluded that the present assay measures biologi­
cally active forms of CCK. Using this assay we found that both in 
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patients with truncal vagotomy and in patients with highly selec-
tive vagotomy the CCK response to the liquid fat meal was in-
creased compared to that in normal subjects and in patients with 
duodenal ulcer. Since all patients had undergone vagotomy because 
of duodenal ulcer disease, these results suggest that vagotomy 
Integrated plasma CCK 
( n m o l / l • 60min ) 
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0 6 
CU 
02 -
normal duodenal highly truncal 
subjects ulcer selective vagotomy 
vagotomy 
(n=8) |n=6) fn^B) (n=6) 
Figure 5 Integrated plasma CCK secretion in response to a liquid 
fat meal (250 ml 20$ Intralipid) in the first hour after 
ingestion in 8 normal subjects, in 6 patients with duo-
denal ulcer, in 8 patients with highly selective vago-
tomy and in 6 patients with truncal vagotomy. 
results in an increase in the plasma CCK response to a liquid fat 
meal. The mechanism for this increased plasma CCK secretion in 
vagotomized patients is unknown, but is probably related to rapid 
gastric emptying in such patients. It has repeatedly been shown, 
that both in patients with truncal vagotomy and in patients with 
highly selective vagotomy the initial gastric emptying of liquid 
meals is increased (3, 11-14). As shown in figures 4 and 5 the 
differences in integrated plasma CCK secretion over 2 hours be-
tween vagotomized patients and non-operated subjects were almost 
•„, 
exclusively due to differences found in the first hour after 
ingestion of the meal. Furthermore, is has recently been reported 
that in patients with partial gastrectomy, another condition cha­
racterized by rapid gastric emptying, the plasma CCK secretion 
after a liquid fat meal is also increased (15). This increased 
CCK secretion in gastrectomized patients was independent of the 
type of anastomosis between the gastric remnant and the small in­
testine ( 15) . 
In conclusion, patients with either truncal or highly selec­
tive vagotomy show an increased CCK secretion in response to a 
liquid fat meal, whereas the CCK secretion in patients with duo­
denal ulcer is similar to that in normal subjects. Therefore, va­
gotomy does not impair the plasma CCK secretion in response to 
nutrients. 
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Abstract 
The present study was undertaken to determine whether bypas­
sing the duodenum in patients with Billroth II gastrectomy af­
fects plasma cholecystokinin (CCK) release in response to inges­
tion of fat. Plasma CCK concentrations were measured by radio­
immunoassay using two antibodies; antibody 1703 binds to all 
C-terminal CCK-peptides containing at least 1Ц amino acid resi­
dues, while antibody Т20Ц is specific for the sulphated tyrosine 
region of CCK. There were no significant differences among fas­
ting plasma CCK concentrations in seven patients with Billroth II 
gastrectomy (1.3 ± 0.1 fmol/ml, antibody 1703; 2.6 ± 0.4 fmol/ml, 
antibody Т20Ч), six patients with Billroth I gastrectomy (0.6 ± 
0.3 fmol/ml, antibody 1703; 2.9 ± 0.5 fmol/ml, antibody Т20І* ) , 
and nine normal subjects (0.7 * 0.1 fmol/ml, antibody 1703; 1.9 ± 
0.3 fmol/ml, antibody T204). Ingestion of 250 ml 20Í Intralipid 
induced similar increases in plasma CCK in patients with Billroth 
II gastrectomy (11.2 ± 2.0 fmol/ml, antibody 1703; 10.1 ± 2.4 
fmol/ml, antibody Т20Ц) as in patients with Billroth I gastrec­
tomy (11.8 ± 2.0 fmol/ml, antibody 1703; 8.4 ± 1.1 fmol/ml, anti­
body T204). However, the increments in plasma CCK in patients 
with gastrectomy (11.5 * 1.4 fmol/ml, antibody 1703; 9-3 ± 1.4 
fmol/ml, antibody T204) were significantly (p < 0.01) greater 
than those in normal subjects (4.7 ± 0.8 fmol/ml, antibody 1703; 
4.1 ± 0.7 fmol/ml). Similarly, the integrated plasma CCK secre­
tion in patients with Billroth II gastrectomy (510 ± 58 fmol/ 
ml'120 min, antibody 1703 458 ± 69 fmol/ml-120 min, antibody 
T204) and in patients with Billroth I gastrectomy (457 ± 143 
fmol/ml · 120 min, antibody 1703; 365 ± 61 fmol/ml-120 min, 
antibody T204) were significantly (p < 0.05) greater than in nor­
mal subjects (230 * 49 fmol/ml-120 min, antibody 1703; 162 ± 24 
fmol/ml-120 rain, antibody T204 ) . 
It is concluded that the plasma CCK response to oral fat is 
significantly greater than in patients with partial gastrectomy 
than in normal subjects, and that patients with Billroth I and 
Billroth II gastrectomy have similar Increases in plasma CCK af­
ter ingestion of fat. 
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Introduction 
Cholecystokinin (CCK) is a polypeptide hormone isolated from 
the mucosa of the upper small intestine, which stimulates gall-
bladder contraction and pancreatic enzyme secretion (1). Before 
the development of reliable radioimmunoassays for CCK in plasma, 
it was generally accepted that the actions of intestinal stimuli 
for gallbladder contraction and pancreatic enzyme secretion were 
mediated by the release of CCK into the circulation. In fact, 
gallbladder contraction and pancreatic enzyme secretion were used 
as bioassay systems for the measurements of CCK in plasma (2,3). 
It is well known that it is very hard to develop a reliable ra-
dioimmunoassay for CCK (t). Several factors contribute to diffi-
culties in developing a radioimmunoassay for CCK, such as diffi-
culties in preparing immunoreactive CCK-labels (5), cross-reacti-
vity of antibodies with gastrin because CCK and gastrin share the 
same five C-terminal amino acid residues (6,7), suspected species 
differences in the chemical structure of CCK (8,9), absence of 
purified or synthetic human CCK, and availability of only limited 
amounts of pure porcine CCK. We have developed radioimmunoassays 
for CCK sufficiently sensitive to measure the low concentrations 
of CCK in human plasma. 
Cholecystokinin is produced by endocrine cells in the mucosa 
of the upper small intestine. Since the highest concentrations of 
CCK are found m the duodenal mucosa (10), it is likely that food 
bypassing the duodenum will result in impaired CCK release and 
decreased stimulation of gallbladder and pancreatic enzyme secre-
tion. The higher incidence of gallstones in patients with Bill-
roth II gastrectomy has been attributed to impaired stimulation 
of gallbladder contraction due to the low postprandial plasma CCK 
concentrations in such patients (11-14). Furthermore, impaired 
postprandial release of CCK in patients with Billroth II gastrec-
tomy has been demonstrated by in vitro gallbladder bioassay (15). 
In the present study we have measured plasma CCK concentra-
tions before and after ingestion of fat in patients with Billroth 
I gastrectomy and Billroth II gastrectomy. The results were com-
pared to those obtained in normal subjects. 
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Subjects and methods 
Thirteen patients with gastrectomy were studied. All patients 
had been operated upon for peptic ulcer. Six of them (four male, 
two female; mean age 1(5 years, range 27-59 years) had Billroth I 
anastomosis, and seven (six male, one female; mean age 51 years; 
range 35-66 years) had Billroth II anastomosis. In addition, nine 
normal subjects (eight male, one female; mean age 40 years; range 
25-62 years) were studied. After an overnight fast the subjects 
ingested 250 ml 20Í Intralipid (Kabi Vitrum, Stockholm, Sweden) 
within 10 minutes. Blood samples for measurement of CCK were ob-
tained at -5, 0, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120 minut-
es. Plasma CCK concentrations were measured by radioimmunoassay 
using two antibodies with different specificities (16). Antibody 
1703 binds to all C-terminal CCK peptides containing at least 14 
amino acid residues and does not show any cross-reactivity with 
gastrin (table 1). Antibody T204 binds to all CCK-peptides con-
taining the sulphated tyrosine region. This antibody shows low 
binding to sulphated gastrins but it does not bind to unsulphated 
gastrins (table 1). 
Table 1 Relative potencies of CCK-peptides and gastrins to anti-
body 1703 and antibody T204 
n t i b o d y 
1703 
0. 
1 . 
0. 
< 0 . 
< 0. 
< 0 . 
< 0. 
< 0 . 
< 0. 
< 0 . 
< 0 . 
0 . 
0 . 
< 0 . 
< 0. 
< 0 . 
< 0. 
.91 
,00 
,62 
,01 
,01 
,01 
,01 
,01 
,01 
,01 
,01 
.01 
,01 
,01 
,01 
,01 
,01 
antibody 
T204 
CCK39 
CCK33 
CCK20-33 
CCK22-33 
CCK24-33 
CCK26-33 sulphated 
CCK26-33 unsulphated 
CCK30-33 
CCK1-21 
CCK1-15 
CCK10-20 
CCK16-27 
CCK20-27 
gastrin 34 sulphated 
gastrin 34 unsulphated 
gastrin 17 sulphated 
gastrin 17 unsulphated 
09 
00 
69 
71 
78 
65 
< 0. 01 
< 0.01 
< 0. 01 
< 0.01 
< 0.01 
0.01 
02 
02 
< 0.01 
0.02 
< 0.01 
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The antibodies do not bind to structurally unrelated regulatory 
peptides, including insulin, glucagon, pancreatic polypeptide, 
somatostatin, secretin, gastric inhibitory polypeptide, vasoac-
tive intestinal polypeptide, bombesin or neurotensin. Measure-
ment of the eluate of a Sephadex G50 column to which an aqueous-
acid extract of human upper small intestine was applied showed 
that both antibodies bind to component I CCK, CCK33-CCK39, and 
intermediate CCK, while antibody T204 binds also to CCK8 (16). 
CCK33 coupled to 125i_hydroxyphenylpropionic acid-succimmide es-
ter (Bolton Hunter reagent) was used as label (16). Ninetynine 
per cent pure porcine CCK33 w a s used as standard. 0.05 mol/1 so-
dium phosphate buffer pH 7.4 containing 0.08 mmol/1 human serum 
albumin and 0.06 mmol/1 sodiumethyImercur11hiosalicyla te was used 
as assay buffer. A nonequilibrlum system was used with 72 hours 
preincubation followed by 24 hours incubation after addition of 
the labelled peptide. Separation between free and antibody-bound 
hormone was performed by adsorption of the free peptide to plas-
ma-coated charcoal. The 50? inhibition dose (ID50) was 2.8 fmol/ 
ml for antibody 1703 and 3.3 fmol/ml for antibody T204. Plasma 
samples were extracted in 96Ï ethanol, dried under nitrogen at 
37°C and reconstituted in assay buffer to the original volume 
before the assay. Recovery of CCK33 and sulphated CCK8 added to 
hormone-free plasma was 85.4 ± 2.0$ (n=11) and 89.8 ± 1.7Í (n=7), 
respectively. The detection limit of both assays was about 0.5 
fmol/ml plasma. The intraassay variation in the working range of 
the standard curve was between 4.6 and 11.5$, and the interassay 
variation ranged from 11.3 t o 26.1$. Dilution curves of plasma 
samples containing a high concentration of endogenous CCK were 
parallel to the standard curve. 
Results were expressed as the mean ± 1 SEM. The integrated CCK 
secretion after ingestion of fat was determined by calculating 
the area under the curve after subtraction of the basal value. 
Statistical analysis was done by Student's t-test for paired and 
unpaired results. Informed consent was obtained from all subjects 
studied . 
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Results 
Fasting plasma CCK concentrations in seven patients with Bill­
roth II gastrectomy (I.3 * 0.Ц fraol/ml, antibody 1703; 2.6 * 0. H 
fraol/ml, antibody 7204) were not significantly different from 
those in six patients with Billroth I gastrectomy (0.6 ± 0.3 
fmol/ml, antibody 1703; 2.9 ± 0.5 fmol/ml, antibody Ί20Η) and 
from those in nine normal subjects (0.7 ± 0.1 fmol/ml, antibody 
1703; 1.9 ± О.З fmol/ml, antibody T204). In normal subjects in­
gestion of fat induced increases in plasma CCK, which reached 
statistical significance (p = 0.0001-p < 0.05) over basal at 10, 
20, 30, 40, 50, 60, 75 and 105 minutes when measured with anti­
body 1703i and at 10, 20, 30» 40, 50, 60 and 75 minutes when 
measured with antibody T204 (p = 0.0005-p < 0.05; fig. 1). Inges­
tion of fat in gastrectomized patients resulted in significant 
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Figure 1 Plasma cholecystokinin concentrations before and after 
oral ingestion of 250 ml 20Ï Intralipid in 13 patients 
with partial gastrectomy (· ·) and in 9 normal sub-
jects (o o ) . The left panel represents the results as 
measured with antibody T204 and the right panel with an-
tibody 1703. Asterisks indicate significant differences 
between patients with gastrectomy and normal subjects. 
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Figure 2 Integrated plasma choleoystokinin secretion after oral 
fat in normal subjects and in patients with gastrectomy 
as measured with antibody 1204 (upper panel) and anti­
body 1703 (lower panel). 
increases in plasma CCK over basal value in all postprandial sam­
ples when measured with antibody 1703 (p < 0.0001-p < 0.05) and 
at 10, 20, 30, HO, 50, 60, 75, 90 and 105 minutes when measured 
with antibody T204 (p < 0.0001-p < 0.05; fig. 1. The plasma CCK 
response to oral fat in the gastrectomized patients was signifi-
cantly greater than in the normal subjects at 10, 20, 30 and Ц0 
minutes when measured with antibody 1703 and in all postprandial 
samples when measured with antibody T20'4 (p < 0.005-P < 0.05; 
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fig. 1). The peak increments in plasma CCK in gastrectomized pa­
tients (11.5 * 1.4 fmol/ml, antibody 1703; 9.3 * 1-3 fmol/ml, 
antibody Т20Ч ) were significantly (ρ < 0.01) greater than those 
in normal subjects ( l|. 7 ± 0.8 fmol/ml, antibody 1703; 4.1 * 0.7 
fmol/ml, antibody 1204). Similarly, the integrated plasma CCK 
secretion after oral fat in gastrectomized patients (486 ± 70 
fmol/ml'120 m m , antibody 1703; 415 ± 47 fmol/ml-120 m m , 
antibody T204) was significantly (p < 0.05) greater than in nor­
mal subjects (229 ± 49 fmol/ml*120 m m , antibody 1703; 162 ± 24 
fmol/ml-120 min, antibody T204; Fig. 2). 
Ingestion of fat induced significant increases in plasma CCK 
in patients with Billroth II gastrectomy at 10, 20, 30, 40, 50, 
60, 75, 90 and 105 minutes when measured with antibody 1703 (p< 
0.0001-p < 0.05) and at 10, 20, 30, 40, 50, 60, 75 and 90 minutes 
when measured with antibody T204 (p < 0.0001-p < 0.05; fig. 3). 
In patients with Billroth I gastrectomy postprandial plasma CCK 
concentrations were significantly increased over basal value at 
10, 20, 30 and 40 minutes when measured with antibody 1703 (p < 
0.005-P < 0.05) and at 10, 20, 30, 40, 50, 75, 90 and 105 minutes 
when measured with antibody T204 (p = 0.001-p < 0.05; Fig. 3). 
The postprandial CCK concentrations were significantly (p < 0.05) 
greater in patients with Billroth II gastrectomy compared to pa­
tients with Billroth I gastrectomy 30 and 40 minutes after inges­
tion of the liquid fat meal as measured with both antibodies 
(Fig. 3). However, the peak increments in plasma CCK in patients 
with Billroth II gastrectomy (11.2 ± 2.0 fmol/ml, antibody 1703; 
10.1 ± 2.4 fmol/ml, antibody T204 ) and in patients with Billroth 
I gastrectomy (11.8 * 2.0 fmol/ml, antibody 1703; 8.4 ± 1.1 
fmol/ml, antibody T204) were not significantly different. Simi­
larly, the integrated plasma CCK secretion after ingestion of fat 
in patients with Billroth II gastrectomy (510 ± 58 fmol/ml·120 
m m , antibody 1703; 458 ± 69 fraol/ml-120 min, antibody T204 ) 
did not significantly differ from that in patients with Billroth 
I gastrectomy (457 ± 143 fmol/ml-120 min, antibody 1703; 365 ± 
61 fmol/ml«120 m m , antibody T204; Fig. 2 ) . 
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Discussion 
The present study confirms our previous findings that basal 
plasma CCK concentrations in normal subjects are low (16). Pa­
tients with partial gastrectomy had similarly low plasma CCK con­
centrations. As expected, ingestion of fat was a potent stimulus 
for CCK release in both normal subjects and patients with gastr­
ectomy. However, the plasma CCK response to oral fat was signifi­
cantly greater in gastrectomized patients than in normal sub­
jects. The mechanisms for this exaggerated plasma CCK response in 
patients with gastrectomy is unknown, but it may be related to 
the rapid gastric emptying in such patients (17). A surprising 
finding was that the plasma CCK secretion after oral fat was si­
milar in patients with Billroth II and Billroth I gastrectomy. 
This finding indicates that large amounts of CCK can be released 
from the jejunum, and that bypassing the duodenum does not affect 
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Figure 3 Plasma cholecystokinin response to oral fat in seven 
patients with Billroth II gastrectomy (· ·) and in 
six patients with Billroth I gastrectomy (o o) as 
measured with antibody T204 (left panel) and antibody 
1703 (right panel). Asterisks indicate significant dif­
ferences between the two groups. 
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the CCK secretion after ingestion of fat. It is not known whether 
the high postprandial plasma CCK concentrations in gast reetomized 
patients induce clinical symptoms. Infusion of high doses of CCK 
stimulates small intestinal motility (18). It may be possible 
that abdominal cramps and diarrhoea after feeding in some gastr-
ectomized patients result, at least in part, from the high circu­
lating CCK concentrations. In fact, most gastrectomized patients 
in the present study complained of abdominal cramps after inges­
tion of fat. Furthermore, it has been reported that patients with 
gastrectomy have an increased incidence of gallstones (11-14). 
The present study shows that this is not due to an impaired post­
prandial CCK secretion, as has been suggested previously (12-
15). However, it has been reported that parenteral administration 
of CCK with meals induces an increase in cholesterol saturation 
of gallbladder bile in man (19). In analogy, it may be possible 
that the high concentrations of endogenous CCK in postprandial 
plasma from gastrectomized patients are involved in the higher 
incidence of gallstones in such patients. 
There is a considerable controversy relating to the molecular 
forms of CCK in human plasma. It has been suggested that a small 
molecular form, possibly CCK8 is the predominant form of CCK re­
leased after feeding (6,7). However, in the present study we 
found large increases in plasma CCK after oral fat when measured 
with antibody 1703. Since antibody 1703 binds to C-terminal CCK 
peptides containing at least 1Ц amino acid residues, it is evi­
dent that large or intermediate forms of CCK are released after 
oral fat. It has recently been shown by high pressure liquid 
chromatography combined with radioimmunoassay that both large and 
small forms of CCK are released after ingestion of a liquid fat 
meal (20). Furthermore, it has been reported that large and 
intermediate forms of CCK are the predominant molecular forms of 
CCK released during infusion of bombesin into humans (21). The 
presence of large molecular forms of CCK in the circulation is of 
physiological relevance, since it has recently been shown that, 
in contrast to previous reports, CCK33 and CCK8 have similar 
potencies in contracting the gallbladder and stimulating pancrea­
tic enzyme secretion (22,23). 
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It is concluded that patients with partial gastrectomy show an 
exaggerated plasma CCK respons to ingestion of fat and that the 
plasma CCK response in patients with Billroth II gastrectomy is 
similar to that in patients with Billroth I gastrectomy. 
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Abstract 
A computerized method for quantification of gallbladder volume 
from real-time sonographs is described. The time required to cal­
culate gallbladder volume by this method was only one to two mi­
nutes compared to eight to twelve minutes using the by hand 
method. The coefficient of variation of 6 calculations of 3 gall­
bladder volumes ranged from 6.2 to 10.0 % for the computer method 
and from 8.6 to 19.3 % for" the by hand method (NS), while the 
coefficient of variation of measurements of 3 gallbladder volumes 
obtained within 5 minutes in each of 6 fasting subjects was be­
tween 6.0 and 22.4 % for the computer method and between 5.2 and 
17.9 % for the by hand method (NS). There was a highly signifi­
cant correlation between gallbladder volumes calculated by compu­
ter and by hand methods (r = 0.97; ρ < 0.001). 
It is concluded that the computerized method described in this 
study allows rapid measurement of gallbladder volumes from sono­
grams . 
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Introduct ion 
For physiological and clinical studies of gallbladder motility 
accurate measurement of gallbladder volume is required. Since in 
such studies a large number of gallbladder volumes have to be 
measured, the method is not allowed to be time consuming. Calcu­
lation of gallbladder volumes by the sum of cylinders method from 
real-time ultrasonographs provides a simple, accurate and non­
invasive method for studying gallbladder size and motility in in­
tact man (1). This method, however, is very time-consuming. 
In the present study a computerized method for rapid calcula­
tion of gallbladder volume by the sum of cylinders method Is des­
cribed . 
Materials and methods 
Longit 
obtained 
dam, The 
Everson e 
udina 
by a 
1 and transverse echograms of 
real-time scanner (Diasonic HA 
Netherlands 
t al 
playing its 1 
hand-held 
tographed 
(1). 
argest 
transducer 
. Aft er 90 
) with a 
In short 
longitui 
, frozen 
degrees 
gest short axis through the 
graphed . 
cylinders 
me, the 1 
to a seri 
The 
meth 
ongit 
es of 
pendlcular to 
(fig. 1). 
equation 
volume is 
The 
(V 
the 
gallbl 
od . To 
udinal 
cy lini 
adder vo 
the gallbladder are 
-1, Siemens, Amster-
3.5 MHz transducer as described by 
, the image of 1 
iinal dimension 
the gallbladder dis-
is obtained by the 
on the oscilloscope screen and pho-
rotation of the 
gallbladder is 
transducer the lar-
obtained and photo-
lume is calculated by the sum of 
calculate the uncorrect 
project! 
Jers of e 
the longitud! 
volume of a 
= 
sum of 
Tr-h.di2/H 
the vol 
on of the gallbl 
qual height whic 
nal axis of th 
single cylinder 
ed gallbladder volu-
adder is divided in-
h diameters are per-
e gallbladder image 
is obtained by the 
= 0.785-h-di2. The uncorrected 
umes of these se parate cylinders: 
η 
V = 0.785-h. J_ Ы І ^ ) , 
i = 1 
where V = volume; h = constant distance of two consecutive paral-
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lel lines perpendicular to the longitudinal axis representing the 
height of one cylinder; dj. = diameter of ith cylinder; η = the 
total number of cylinders in the series; 
η 
Л (d12) = the sum of the η squares dj^, through dn . 
i=1 
The correction factor E is introduced to correct for the displa­
cement of the longitudinal image D from the central axis resul­
ting m an apparant decrease in the diameter of the gallbladder 
measured from the longitudinal scan.The correction factor is cal­
culated by the formula E = APdiam + width, where E = correction 
2dmax 
factor; APdiam = anteroposterior diameter of the gallbladder on 
the transverse sonogram; width = the width of the gallbladder on 
transverse sonogram; dmax = greatest diameter of the gallbladder 
on the longitudinal sonogram. Using this correction factor the 
longitudinal scan 
d max 
0 7 8 5 h Г. ( d?) 
ι 1 
transverse scan 
APdiam 
width 
χ )APdiam » width 
2d max 
! Volume = uncorrected volume | χ (correction factor)2] 
Figure 1 Schematic representation of the calculation method of 
gallbladder volume by the sum of cylinders method. Gall­
bladder volume is the uncorrected volume times the 
square of the correction factor. Uncorrected volume is 
the sum of cylinders with diameter dj^  and heigt h. The 
correction factor is calculated from the greatest dia­
meter, dmax, on the longitudinal projection and the an­
teroposterior diameter, APdiam, and width of the trans­
verse projection. For details see text. 
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formula for calculation of gallbladder volume is: 
η 
V = 0.785-h-E2.I. (d 12). 
i=1 
In the method by hand the longitudinal contour of the gall­
bladder is traced on paper. The diameters of the parallel lines 
with a constant distance of 1 mm perpendicular to the longitudi­
nal axis are measured. Since gallbladder photographs are on a re­
duced scale, a scaling factor is obtained from two points on the 
sonogram with a known distance to correct for this reduction. Af­
ter measuring the anteroposterior diameter and width of the gall­
bladder on the transverse scan, the gallbladder volume can be 
calculated by the above-mentioned formula. Measurement of one 
gallbladder volume using this "by hand method" requires between 8 
and 12 minutes . 
In the computer method a sonic digitizer (Graf/Pen, Science 
Accessories Corporation, Southport, Connecticut, USA) and a digi­
tal computer (PDP ІІ/З1·, Digital Equipment Corporation, Maynard, 
Massachusettes, USA) are employed. The computer Program GALVOL 
was written in Fortran by one of the authors (W.B.). The flow 
diagram is shown in figure 2. The longitudinal contour is entered 
from the gallbladder photograph on the light table of the sonic 
digitizer by tracing it with the sonic digitizer stylus. The 
orientation of the longitudinal axis of the gallbladder is enter­
ed by touching two points on this axis with the digitizer 
stylus. A scaling factor is obtained by touching two points on 
the sonogram which are separated from each other by a known dis­
tance. When the contour has been formed, it is displayed on the 
screen of a graphical storage oscilloscope display (Tektronix 
4006-1, Beaverton, Oregon, USA) for approval. The longitudinal 
axis of the contour is chosen as the X-axis of the contours 
coordinate system. The diameters (dj^ ) in the longitudinal projec­
tion can be calculated from the coordinates of the intersections 
of lines drawn at 2 mm intervals perpendicular to the x-axis and 
the polygon which describes the contour. The anteroposterior dia­
meter and the width of the gallbladder in the transverse projec­
tion are also entered via the sonic digitizer. From these two 
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Figure 2 (p.76-77) 
Flow diagram of program GALVOL 
for rapid computerized calcula-
tion of gallbladder volume 
from sonograms. 
L identification of p j i ient Ï;:;: 7 
get scale of 
longitudinal 
sonogram 
get longitudinal 
gallbMdder contour 
and 
orientation of 
longitudinal axis 
displav ol rotated 
contour u i t h 
calculated diameiers 
and uncorrected 
\ olume 
77 
values together with the maximum value of dj^  (=dmax), the correc­
tion factor E can be calculated. The uncorrected and the correct­
ed gallbladder volume are displayed on the computer terminal or 
can be printed out on the systems printer. The time required for 
calculation of one gallbladder volume by the computer method is 
between one and two minutes. 
Results 
Since calculation of gallbladder volume by hand using the sum 
of cylinders method has been carefully validated (1), comparison 
between volumes calculated by computer with those obtained using 
the by hand method will provide information on the reliability of 
the computerized method. In six consecutive subjects who partici­
pated in a study on gallbladder motility five echograms were ran­
domly chosen from the HO echograms made in each person. Gallblad­
der volume was calculated both by hand and by computer. There was 
a very significant correlation between gallbladder volumes 
measured by the two methods (r r 0.97; ρ < 0.001; flg. 3). The 
variation of sixfold calculation of 3 gallbladder volumes ranged 
from 6.2 to 10.0$ for the computer method and from 8.6 to 19.3 
for the by hand method (NS). The coefficient of variation of 
measurements of 3 gallbladder volumes obtained within 5 minutes 
m each of 6 fasting subjects was between 6.0 and 22.4 for the 
computer method and between 5.2 and 17.956 for the by hand method 
(NS). Assuming that basal gallbladder volumes are constant for at 
least 5 minutes, the results can be considered as a good estimate 
of precision of ultrasound measurement of gallbladder volume. 
Discussion 
Real-time ultrasonography as an accurate means of quantifying 
gallbladder volume and contraction obviates the need for intuba­
tion to aspirate duodenal juice and the risk of radiation expo­
sure (1). Calculation of gallbladder volumes by the sum of cylin-
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ders method, however, can be rather time-consuming (2). Wiener et 
al (3) have attempted to circumvent this problem by calculating 
gallbladder volumes from sonograms using the single cylinder 
method. This method, however, has been demonstrated to be less 
accurate than the sum of cylinders method (1). In a later study 
these authors corrected the volumes obtained by the single cylin­
der method to the more accurate "sum of cylinders method" volumes 
(4) which, however, may lead to considerable errors in individual 
cases . 
Volume by computer (cm 3 ) 1 
6 0 
4 0 
2 0 
ι ι ι 1 1 
20 4 0 
Volume by hand ( c m 3 ) 
Figure 3 Correlation between gallbladder volumes calculated by 
the computer and the by hand methods. 
The computerized method described in this study allows rapid 
measurement of gallbladder volumes from real-time sonographs 
using the sum of cylinders method. 
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CHAPTER VII 
COMPARISON BETWEEN GALLBLADDER CONTRACTION MEASURED BY 
ULTRASONOGRAPHY AND BY INTRADUODENAL BILIRUBIN OUTPUT DURING 
STEPWISE INCREASING DOSES OF CHOLECYSTOKININ 
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Abstract 
For several years gallbladder contraction has been quantified 
by measuring bilirubin output into the duodenum, while more 
recently real-time ultrasonography is used to measure gallbladder 
contraction. This study was undertaken to compare measurements of 
gallbladder contraction by intraduodenal bilirubin output and by 
ultrasonography during infusion of stepwise increasing "physiolo­
gical" doses of cholecystokinin (CCK) in man. Plasma CCK was 
measured by radioimmunoassay using antibody 1204, which binds to 
all carboxyl-terminal CCK-peptides containing the sulphated tyro­
sine region. Infusion of 0.2, 0.1), 0.8, 1.6, 3.2 and 6 . Ц 
pmol/kg.hr CCK33 increased plasma CCK from a basal level of 1.7 ± 
0.2 to 2.4 ± 0.7 (n.s.), 2.6 ± 0.4 (p< 0.05), 2.9 * 0.5 (p< 
0.05), 3.7 ± 0.5 (p < 0.005), 4.6 ± 0.6 (p< 0.005) and 6.9 ± 0.8 
(p = 0.0005) pmol/1, respectively. There was a highly significant 
correlation between the amounts of CCK infused and the increases 
in plasma CCK (r = 0.9788; ρ < 0.001). Infusion of CCK induced 
stepwise increases in intraduodenal bilirubin output and decreas­
es in gallbladder volume. The correlation between intraduodenal 
bilirubin outputs and decreases in gallbladder volumes was highly 
significant (r = 0.9773; Ρ < 0.001). Infusion of 0.8 pmol/kg.hr 
CCK33, resulting in an increase in plasma CCK of 1.3 ± 0.5 
pmol/1, was the threshold for stimulating gallbladder contraction 
as assessed by both methods. 
It is concluded that ultrasonography and intraduodenal 
bilirubin output are equally sensitive in the quantification of 
gallbladder contraction and that because of its simplicity 
ultrasonography is the preferred method for studying gallbladder 
contraction. This study further shows that "physiological" plasma 
concentrations of CCK stimulate gallbladder contraction in man. 
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Introduction 
Previously, several methods have been employed to quantify 
gallbladder contraction. Serial radiography (1) and scintigraphy 
(2) have the disadvantage of radiation exposure, while measure-
ment of intraduodenal output of bilirubin or bile acids requires 
intubation and a skillful staff (3-5). In several recent studies 
ultrasonography has been used for quantification of gallbladder 
contraction (6-13). However, the reliability of this method has 
not been compared with methods previously employed. 
Since it has been shown that measurement of intraduodenal bi-
lirubin output is an accurate method for quantification of gall-
bladder contraction (4), we have compared decreases in gallblad-
der volume determined by real-time ultrasonography and by intra-
duodenal bilirubin output during infusion of stepwise increasing 
doses of CCK33 in normal subjects. Since we were especially inte-
rested in the sensitivity of both methods, low doses of CCK were 
infused resulting in physiological plasma CCK concentrations. 
Subjects and Methods 
Eight healthy volunteers, 5 male and 3 female, mean age 22, 
with a range of 20 - 27 years, were studied. After an overnight 
fast a triple lumen tube was positioned under fluoroscopic con-
trol. The proximal openings were located in the gastric antrum 
and were used for aspiration of gastric juice, the middle opening 
was located in the proximal duodenum and was used for perfusion 
of PEG 4000 as a recovery marker, while the distal openings were 
located at Treitz and were used for collection of duodenal 
Juice. Total radiation exposure was 0.8 rads per subject. PEG 
4000 (66.7 g/1) was perfused at a flow rate of 30 ml/hr After a 
basal sampling period of 30 minutes each subsequent 30 minutes an 
increasing step dose of CCK33 was infused. The maximal number of 
doses administered on one morning to one subject was 6. Four sub-
jects were studied on two separate mornings. On the 6 different 
doses tested (0.2, 0.4, 0.8, 1.6, 3.2 and 6.4 pmol/kg.hr) 6, 8, 
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11, 11, 8 and 7 observations were done, respectively. Duodenal 
juice was pooled in 10 minutes portions. Furthermore, every 10 
minutes a blood sample for CCK measurement was drawn and 3 images 
of the gallbladder were made by ultrasonography. Gallbladder vo-
lumes were calculated by the sum of cylinders method (7) and the 
mean of three measurements was used. The variation of this method 
ranged from 10.0 to 17.5 $. CCK was measured in plasma and in 
samples of the infúsate, obtained from the tip of the infusion 
line, by a sensitive and specific radioimmunoassay (14,15). Anti-
body T204, raised in a rabbit after the fourth immunization with 
albumin-coupled CCK was used in a dilution of 1 : 80,000. The an-
tibody binds to all carboxy1-terminal CCK-peptides containing the 
sulphated tyrosine region. 99$ pure porcine CCK33 was used as 
standardand after coupling to 125i_hydroxyphenylpropionic acid-
succinimide ester (Bolton-Hunter reagent) as label. The detection 
limit of the assay was between 0.5 and 1.0 pmol/1 plasma. The in-
tra-assay precision was 11.5Í at 1.2 pmol/1, 8.4$ at 2.5 pmol/1 
and 4.6$ at 8.0 pmol/1 (n = 5), while the interassay precision 
was 26.1 $ at 1.3 pmol/1, 11.3$ at 2.6 pmol/1 and 15.4$ at 8.8 
pmol/1 (п=5). Bilirubin and PEG 4000 in duodenal juice were 
measured by methods previously described (16,17)· 
Results were expressed as the mean ± 1 SEM. The mean of plasma 
CCK concentrations obtained at 10, 20 and 30 minutes was calcula­
ted for each infusion period, while the mean of gallbladder volu­
mes measured at 20 and 30 minutes was used for quantifying gall­
bladder contraction. Bilirubin output was calculated from the cu­
mulative outputs over 30 minutes after subtraction of the basal 
value. Statistical analysis was done by Student's t-test for 
paired results. Correlation coefficients were calculated by li­
near regression analysis. To determine whether there were dose-
response relations between the doses of CCK infused and the in­
creases in plasma CCK, decreases in gallbladder volume and intra-
duodenal outputs of bilirubin, the average slope of the linear 
regression for each response variable, computed on log dose for 
each subject, was compared with zero by means of a t-test (18). 
Informed consent was obtained from all subjects studied. 
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Figure 1 The effect of infusion of stepwise increasing doses of 
CCK33 on intraduodenal bilirubin output, decreases in 
gallbladder volume аз measured by ultrasonography, in­
crements in plasma CCK and infusion rates of CCK as 
measured from the tip of the tubing. Asterisks denote 
significant differences from basal values (* ρ < 0.05; 
ι· 
ρ < 0.01 ; ··· ρ < 0.005) . 
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Results 
In the basal state plasma CCK was 1.7 ± 0.2 pmol/1, gallblad­
der volume 28.8 ± 2.4 сгаЗ and bilirubin output 1.5 ± 0.U mol/30 
min. Infusion of 0.2, 0.4, 0.8, 1.6, 3.2 and 6.4 pmol/kg.hr CCK33 
increased plasma CCK from a basal level of 1.7 ± 0.2 to 2.4 * 0.7 
(NS), 2.6 ± 0.4 (p < 0.05), 2.9 ± 0.5 (p < 0.05), 3-7 * 0.5 (p< 
0.005), 4.6 ± 0.6 (p < 0.005) and 6.9 ± 0.8 (p = 0.0005) pmol/1, 
respectively (fig. 1). As shown in figure 2, there was a highly 
significant correlation between the amount of CCK infused and the 
increments in plasma CCK (r = 0.9788; ρ < 0.001). When 
Plasma CCK increment 1 
( p m o l / l ) 
5 
Λ -
3 
2 
1 
0 - -
ι 1 1 1 ' 
О 2 Λ 6 θ 
Plasma CCK infusion rate ( p m o l / k g . h r ) 
(measured) 
Figure 2 Correlation between the amounts of CCK33 infused and the 
increases in plasma CCK (r = 0.9788; ρ < 0.001). 
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Figure 3 Correlation between plasma CCK incrementa during infu­
sion of stepwise increasing doses of CCK33 and decreases 
in gallbladder volume as measured by ultrasonography (r 
= 0.9671; Ρ < 0.001 ) . 
CCK was infused in doses of at least 0.8 pmol/kg.hr gallbladder 
volume, measured by ultrasonography, decreased significantly 
(fig.1). There was a significant correlation between the amount 
of CCK infused and gallbladder contraction (r = 0.9381; p< 
0.01). Furthermore, gallbladder contraction was significantly 
correlated to the increments in plasma CCK (r = 0.9671; P< 
0.001; fig. 3). Similar to decreases in gallbladder volume, sig­
nificant increases in intraduodenal bilirubin output were observ­
ed during infusion of CCK in doses of at least 0.8 pmol/kg.hr 
(fig. 1). Intraduodenal bilirubin output was significantly corre­
lated to the amount of CCK infused (r r 0.9^81; ρ < 0.01) and to 
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Figure 4 Correlation between plasma CCK increments during infu­
sion of stepwise increasing doses of CCK33 and cumula­
tive bilirubin output into the duodenum (r r 0.9502; p< 
0.01 ) . 
the increments in plasma CCK (r = 0.9502; ρ < 0.01; fig. 4). As 
shown in figure 5. there was a significant correlation between 
intraduodenal bilirubin output and decreases in gallbladder 
volume as measured by ultrasonography (r = 0.9773; ρ < 0.001). 
Infusion of 0.8 pmol/kg.hr CCK, resulting in an increase in plas­
ma CCK of 1.3 ± 0.5 pmol/l, was the threshold for stimulation of 
gallbladder contraction as determined by both methods (fig. 1). 
The average slope of the linear regression of the amounts of CCK 
infused and increments in plasma CCK (a = 2.92 ± 0.57; ρ = 
0.0014), decreases in gallbladder volume (a = 15.30 ± 1.97· ρ = 
Θ8 
ρ = 0.0001) and bilirubin outputs (a = 68.4 ± 15.1; ρ = 0.0026) 
on log dose for each subject was significantly greater than zero, 
indicating the presence of dose-response relations between the 
amounts of CCK and plasma CCK increments, decreases in gallblad­
der volume and bilirubin outputs. Sephadex G 50 column chromato­
graphy showed that CCK both in the infúsate and in plasma during 
infusion of CCK co-eluted with the CCK33 standard (data not 
shown ) . 
Discussion 
Several methods have been employed to quantify gallbladder 
contraction. Serial radiography and scintigraphy have the disad-
vantage of radiation exposure (1,2). Measurement of bilirubin or 
bile acid output into the duodenum is an accurate method for 
quantifying gallbladder contraction, but it requires intubation 
with fluoroscopic control of the position of the tube (3-5). In 
several recent studies real-time ultrasonography is used to 
quantify gallbladder contract ion(6-13)· Ultrasonography is easily 
performed and does not have the disadvantage of radiation expo-
sure or intubation. However, no studies comparing gallbladder 
contraction measured by ultrasonography and by intraduodenal 
bilirubin output have been performed. Therefore, we have measured 
intraduodenal bilirubin output and decreases in gallbladder 
volume by ultrasonography during infusion of stepwise increasing 
doses of CCK33· Since we were especially interested in the lowest 
increase in plasma CCK inducing gallbladder contraction and in 
the sensitivity of both methods for the quantification of 
gallbladder contraction, we have infused relatively low doses of 
CCK resulting in plasma CCK concentrations in the physiological 
range, i.e. lower or similar to those found after ingestion of a 
meal . 
Decreases in gallbladder volume by ultrasonography were highly 
significantly correlated to intraduodenal bilirubin outputs. 
Infusion of 0.8 pmol/kg.hr CCK, inducing an increase of plasma 
CCK of 1.3 ± 0.5 pmol/1, was the threshold for stimulation of 
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gallbladder contraction as assessed by both methods. This indi­
cates that ultrasonography is equally sensitive and accurate in 
the quantification of gallbladder contraction as measurement of 
intraduodenal bilirubin output. Because ultrasonography is easy 
to perform without the need for intubation, this method is to be 
preferred to measurement of intraduodenal bilirubin output. A 
disadvantage of measurement of gallbladder volumes by ultrasono­
graphy is the time required for calculation of the volume by the 
sum of cylinders method. Unfortunately, the single cylinder 
method, which is much less time-consuming, is less accurate than 
the sum of cylinders method (7). Using a computerized method we 
Decrease in gallbladder , 
volume (cm3 ) 
30-
25-
20-
15-
10-
5-
0- -
ι 1 1 1 
0 25 50 75 100 
Bilirubin output ( umol / 30min) 
between decreases in gallbladder volume as 
ultrasonography and cumulative bilirubin 
the duodenum during infusion of stepwise 
oses of CCK33 (r = 0.9773; Ρ 0.001). 
90 
Figure 5 Correlation 
measured by 
output into 
increasing d 
could reduce the time required for calculation of one gallbladder 
volume from about 10 to 1.5 minutes (Hopman et al, unpublished). 
It was further shown that infusion of 0.8, 1.6, 3.2 and 6. 4 
pmol/kg.hr CCK, inducing dose-dependent increases in plasma CCK 
ranging from 1.3 to 5.3 pmol/1, dose dependently stimulated gall­
bladder contraction. Since we have previously shown that in man 
ingestion of fat (13) or a mixed meal (10), intraduodenal instil­
lation of fat (20) and infusion of bombesin (15) induce increas­
es in plasma CCK exceeding I.3 pmol/1, it is likely that CCK, re­
leased in response to these stimuli, plays a physiological role 
in the stimulation of gallbladder contraction in man. These fin­
dings are in agreement with a previous study showing that infu­
sion of CCK, resulting in plasma levels comparable to those found 
after a fatty meal, induces gallbladder contraction in man (21). 
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Effect of equimolar amounts of long-chain 
triglycerides and medium-chain triglycerides on 
plasma cholecystokinin and gallbladder 
contraction1-3 
Wim PM Hopman, MD, Jan BMJ Jansen, MD, Gerd Rosenbusch, MD, and 
Cornells Β H M'Lamers, MD 
ABSTRACT The present study was undertaken to compare the effects of equimolar amounts 
of long-chain triglycérides (LCT) and medium-chain inglycendes (MCT) on plasma cholecysto-
kinin (CCK) concentrations and gallbladder contraction in man. On separate mornings and in 
random order six healthy volunteers ingested either 60 mmol LCT or 60 mmol MCT. Plasma 
CCK concentrations were measured by a sensitive and specific radioimmunoassay and gallbladder 
contraction by ultrasonography Ingestion of LCT induced significant increases in plasma CCK 
from 2.8 ± 0.5 to 6.5 ± 0.7 pmol/1 (p < 0.005) and decreases in gallbladder volume from 33.4 ± 
5.9 to 13.2 ± 4.2 cm3 (p < 0.005). On the other hand, no significant changes in plasma CCK 
and gallbladder volume were found after MCT. Ingestion of MCT was followed by abdominal 
cramps and diarrhea, while LCT were without side effects. It is concluded that, in contrast to 
LCT, MCT do not induce CCK release and gallbladder contraction. Am J Clin Nuir 
1984;39.356-359 
KEY WORDS Long-chain triglycérides, medium-chain Inglycendes. gallbladder, cholecys-
tokinin. radioimmunoassay, ultrasonography 
Introduction 
Approximately 97% of fat in the average 
Western diet is in the form of long-chain 
triglycerides (LCT), containing fatty acids of 
over 14 carbon chain lengths (1). Medium-
chain triglycerides (MCT), containing fatty 
acids with a chain length varying from 6 to 
12 carbon atoms, have been advocated in 
the treatment of patients with malabsorp-
tion, because MCT are rapidly hydrolyzed 
and absorbed (1-3). It has been shown that 
fat is a powerful stimulus for cholecystokinin 
(CCK) release and subsequently for gallblad-
der contraction and pancreatic enzyme se-
cretion (4-7). 
Herein, we have compared the effects of 
equimolar amounts of LCT and MCT on 
The American Journal of Clinical Nutnlion 39. MARCH 1984, pp 356-359 Pnnted in U.S.A. 
© 1984 Amencan Society for Clinical Nutnlion 
plasma CCK and gallbladder contraction in 
healthy volunteers. 
Subjects and methods 
Six male healthy volunteers, age 22 to 38 yr, were 
studied. After an overnight fast, on separate mornings, 
and in random order they ingested within 1 mm either 
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EFFECT OF LCT AND MCT ON ССК 
60 mmol LCT (com oil, Onderlinge Pharmaceutische 
Groothandel, Utrecht, The Netherlands) or 60 mmol 
MCT (Ceres-MCT-dietary oil. Van den Bergh and Jür-
gens, Rotterdam, The Netherlands). The fatty acid com-
position of com oil was palmitic acid (C16 0) 7%, stearic 
acid (CI8.0) 3%, oleic acid (CI8 1) 44%. and linoleic 
acid (CI 82) 39%, while MCT oil contained 58% octan-
oic acid (C8 0) and 39% decanoic acid (C10 0). Blood 
samples for measurement of CCK were obtained at - 5 , 
0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, and 90 mm 
Plasma CCK concentrations were measured by a sen-
sitive and specific radioimmunoassay as described pre-
viously (7-9). The CCK-antibody (T204) binds to all 
CCK-peptides containing the sulfated tyrosine region. 
By studying the eluate of a Sephadex G50 column to 
which an aqueous-acid extract of human upper small 
intestine was applied, it was shown that the antibody 
binds to component I CCK, CCK33-CCK39, interme-
diate CCK, and CCK8 Ninety-nine percent pure 
CCK33 coupled to '"I-hydroxyphenylpropionic acid 
succinimide ester (Bolton-Hunter reagent) was used as 
label and 99% pure CCK33 was used as standard prep-
aration The detection limit of the assay was 0 5 pmol/ 
I plasma. The intraassay variation ranged from 4 6 to 
115% and the interassay variation from 11.3 to 26 I % 
Blood samples were measured in duplicate Every time 
a blood sample was drawn, three longitudinal and three 
transverse sonographs of the gallbladder were made 
using a real-time scanner (Diasonic RA-1. Siemens, 
Amsterdam, The Netherlands) The gallbladder volume 
was estimated by the sum of cylinders method, as 
described by Everson et al (10). The mean of three 
measurements was used for calculation of the results. 
Results were expressed as the mean ± 1 SEM. Inte-
grated CCK secretion was determined by calculating 
the area under the curve after subtraction of basal 
values When plasma CCK concentrations were below 
the basal level the results were subtracted Statistical 
analysis was done by "Student's" / test for paired results. 
Informed consent was obtained from all subjects stud-
ied 
Results 
Ingestion of LCT induced significant in-
creases in plasma CCK concentrations (Fig 
1). In all samples drawn after LCT plasma 
CCK levels were significantly (p < 0.05 to 
0.0005) increased over basal value. The peak 
CCK concentration was found 30 min after 
ingestion of LCT. On the other hand, inges-
tion of MCT did not result in significant 
changes in plasma CCK concentrations (Fig 
I). At 15, 20, 25, 40, 50, 60, 75, and 90 min 
plasma CCK concentrations after LCT were 
significantly (p < 0.05 to 0.005) higher than 
those found after MCT (Fig 1). Similarly, 
the integrated plasma CCK secretion after 
LCT (230 ± 35 pmol/1.90 min) was signifi-
cantly (p < 0.005) higher than that found 
after MCT (-11 ± 35 pmol/1.90 min). 
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FIG 1. Effect of LCT (closed circles) and MCT 
(open antes) on CCK concentrations in six healthy 
subjects Aslensks denote significant differences be­
tween plasma CCK concentration after LCT and MCT 
Ingestion of LCT was followed by signifi­
cant (p < 0.05) decreases in gallbladder vol­
ume as measured by ultrasonography (Fig 
2). At 20, 25, 30, 40, 50, 60, 75, and 90 min 
gallbladder volume was significantly (p < 
0.05 to 0.0005) smaller than basal gallblad­
der volume. Maximum decrease in gallblad­
der volume (64 ± 8%) was found 40 min 
after ingestion of LCT. Ingestion of MCT 
did not significantly change gallbladder vol­
ume (Fig 2). At 20, 25, 30, 40, 50, 60, 75, 
and 90 min gallbladder volume after LCT 
was significantly (p < 0.01 to 0.0001 ) smaller 
than after MCT. In all subjects ingestion of 
MCT was followed by abdominal cramps 
and diarrhea, while no side effects were ob­
served after LCT. 
Discussion 
Since MCT are rapidly hydrolyzed and 
absorbed, they have been advocated in the 
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FIG 2 EfTecl of LCT (closed circles) and MCT 
(open anles) on gallbladder volume as measured by 
ultrasonography in six healthv subjects Results are 
expressed as percentage of basal volume AUensks de-
note significant differences between gallbladder vol-
umes after LCT and MCT 
treatment of patients with malabsorption 
(1-3) MCT differ from LCT in several re-
spects (2) 1) MCT are more rapidly and 
completely hydrolyzed in the intestinal lu-
men by pancreatic enzymes, 2) presence of 
bile in the lumen is not necessary for normal 
absorption of MCT. 3) MCT may be ab-
sorbed intact by the small intestine and are 
completely hydrolyzed in intestinal mucosal 
cells, 4) the small intestine has a greater 
capacity to absorb MCT than LCT, 5) fatty 
acids denved from MCT are transported 
principally by the portal vein and not by the 
intestinal lymphatics, 6) MCT absorption 
does not involve chylomicron formation, 7) 
medium-chain fatty acids are more rapidly 
oxidized than those of long-chain length 
The present study showed that ingestion 
of MCT did not induce release of CCK, 
whereas LCT induced significant increases 
in plasma CCK CCK is known to stimulate 
gallbladder contraction and pancreatic en-
zyme secretion (11, 12) Previous reports 
have shown that the increases in plasma 
CCK after LCT are accompanied by con-
traction of the gallbladder (13, 14) In one 
of these studies there was an excellent cor-
relation between concentrations of CCK in 
plasma and gallbladder size during both con-
traction and relaxation phases (13) It can 
therefore be assumed that ingestion of MCT 
does not induce gallbladder contraction and 
pancreatic enzyme secretion Indeed, the 
present study showed that, in contrast to 
LCT, MCT did not provoke gallbladder con-
traction Since bile is not required for hy-
drolysis and absorption of MCT (1-3), the 
lack of gallbladder contraction will probably 
not affect absorption of MCT On the other 
hand, since only a small amount of MCT 
may be absorbed in the absence of pan-
creatic lipase (1-3, 15), it can be assumed 
that the lack of CCK release and subsequent 
stimulation of pancreatic enzyme secretion 
will result in impaired hydrolysis of MCT 
This impaired hydrolysis of MCT may be 
involved in the mechanism of diarrhea in-
duced by MCT It has been reported that 
during administration of MCT a small num-
ber of patients with malabsorption complain 
of abdominal cramps and diarrhea (1-3) In 
the present study it was shown that ingestion 
of only 30 ml MCT oil induced abdominal 
cramps and diarrhea in all six healthy sub-
jects studied It is remarkable to note that in 
some other studies, in which similar or larger 
amounts of MCT were administered to 
healthy subjects, these side effects were not 
reported (16, 17) The mechanism whereby 
MCT induce diarrhea has not been eluci-
dated It has been suggested that the diarrhea 
is secondary to the rapid hydrolysis of MCT 
resulting in the formation of osmotically 
active fatty acids (1-3) However, the present 
study suggests that the diarrhea may result 
from impaired hydrolysis of MCT due to 
the lack of stimulation of pancreatic enzyme 
secretion by CCK 
The reason for this lack of stimulation of 
CCK release by MCT is not known It has 
been shown both in man and in dog that 
pancreatic enzyme secretion in response to 
intestinal perfusion with fatty acids is related 
to the chain length of the fatty acids ( 18. 19) 
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In dogs, intestinal perfusion with fatty acids 
of less than nine carbons in chain length did 
not stimulate pancreatic enzyme secretion 
(18). while intraduodenal instillation of oc-
tanoic acid in man induced only a weak 
stimulation of pancreatic enzyme secretion 
(19). These studies suggest that the release 
of CCK in response to fatty acids is depend­
ent on the chain length of the fatty acids. 
Furthermore, in man an inverse correlation 
was found between fatty acid absorption and 
pancreatic and gallbladder responses to fatty 
acids, suggesting a relationship between the 
length of intestine exposed to fatty acids and 
the amount of CCK released (19). Since 
medium-chain fatty acids are rapidly ab­
sorbed. only a small part of the upper small 
intestine is exposed to these fatty acids, re­
sulting in low stimulation of CCK secretion. 
An alternative explanation is related to the 
finding that luminal triglycerides do not 
stimulate pancreatic enzyme secretion un­
less conditions are met that favor lipolysis 
(18). The present study suggests that in the 
absence of stimulation of CCK secretion, 
conditions may be unfavorable for adequate 
lipolysis of MCT. It is unlikely that the 
absence of CCK release and gallbladder con­
traction after ingestion of MCT results from 
alterations of motility. Slow gastric empty­
ing of MCT is highly unlikely, because the 
onset of abdominal cramps and diarrhea was 
usually within 2 h after ingestion. Further­
more, we have recently shown that rapid 
gastric emptying does not impair plasma 
CCK secretion after LCT (20). 
In conclusion the present study shows 
that, in contrast to LCT, MCT do not induce 
CCK-secretion and gallbladder contraction 
in man. ЕЭ 
The authors are indebted to Wilma Franssen, Elly 
Sax. and Denise Bell for technical assistance 
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CHAPTER IX 
PLASMA CHOLECYSTOKININ, PLASMA PANCREATIC POLYPEPTIDE AND 
GALLBLADDER RESPONSES TO AN ELEMENTAL DIET IN MAN 
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Abstract 
Since elemental diets are recommended in апоиз gastrointes­
tinal and extragastrointest inai disorders, the present study was 
undertaken to investigate the effect of oral ingestion of 80 g 
vivonex on plasma cholecystokinin (CCK) and pancreatic polypep­
tide ( PP ) levels and on gallbladder volume in 6 healthy sub­
jects. The results were compared to those obtained after oral in­
gestion of 60 ml corn oil. Plasma CCK rose from 0.6 ± 0.1 pmol/1 
to Ц.5 ± 0.8 pmol/1 after vivonex (p < 0.01) and to 5.0 ± 1.1 
pmol/1 after corn oil (p < 0.01). Integrated plasma CCK secretion 
after vivonex (182.4 ± 35.0 pmol/1-90 min) was not significant­
ly different from that after corn oil (272.8 ± 63.I pmol/1'90 
min). Both meals had only minor effects on plasma PP levels. 
Gallbladder volume decreased significantly both after vivonex and 
corn oil. Maximal contraction after vivonex (52 ± 10%) was smal­
ler (p < 0.01) than that after corn oil (81 ± 5Ï). Both after vi-
vonex (r = -O.8O86, ρ < 0.01 and after corn oil (r ζ -0.8H55, ?< 
0.001) a significant inverse correlation was observed between 
plasma CCK levels and gallbladder volumes. 
It is concluded that oral ingestion of vivonex stimulates CCK 
secretion and gallbladder contraction in man. 
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Introduction 
Elemental diets have been advocated in various gastrointestin-
al and extragastrointest inai disorders (1-6). The efficacy of 
such diets has only rarely been documented in controlled trials 
(1). Much interest has been focused on the effect of elemental 
diets in patients with pancreatic disease (acute and chronic pan-
creatitis, pancreatic fistula). Several clinical reports have 
suggested that, because of its weak stimulating effect on the 
pancreas, elemental diets may be of value in clinical situations 
in which rest to the pancreas is thought to be beneficial (6-9). 
Since cholecystokimn (CCK) is a major hormonal mediator of post-
prandial enzyme secretion by the pancreas, these data suggest 
that elemental diets are only weak stimulants of CCK release from 
the small intestinal mucosa. Because CCK is also involved in 
postprandial gallbladder emptying, elemental diets might be 
accompanied by gallbladder stasis with subsequent sludge and 
stone formation (10). Pancreatic polypeptide (PP) is by now the 
only known hormone which, at physiological postprandial levels, 
inhibits both pancreatic enzyme secetion and gallbladder contrac-
tion (11-15). 
The present study was therefore undertaken to determine plasma 
CCK and plasma PP responses to oral ingestion of vivonex. Fur-
thermore, gallbladder contraction was assessed by measuring gall-
bladder volumes by real-time ultrasonography. The results were 
compared to those observed after oral ingestion of corn oil, a 
potent stimulant of CCK secretion and gallbladder contraction 
(16). 
Subjects and methods 
Six healthy subjects (5 male, 1 female; age 23-39 years) 
volunteered m this study. After an overnight fast they ingested 
on separate mornings and in random order 80 g Vivonex" (Norwich 
Benelux, Utrecht, The Netherlands) dissolved in 300 ml water, and 
60 ml corn oil (Onderlinge Pharmaceutische Groothandel, Utrecht, 
103 
The Netherlands). Both meals were ingested within 5 minutes. 
Vivonex contained 8. 1 % amino acids, ^ . H% fat and 90.5% carbohy-
drate. In 80 g vivonex there were 2.37 g essential and 3.83 g 
non-essential amino acids. Blood samples for measurement of CCK 
and PP were obtained at -5, 0, 5, 10, 15. 20, 25, 30, 10, 50, 60, 
75 and 90 minutes. Each time a blood sample was drawn three long-
itudinal and three transverse sonographs of the gallbladder were 
made with a real-time scanner (Diasonic RA-1, Siemens, Amsterdam, 
The Netherlands) according to a previously described method 
(16,17). Gallbladder volume was calculated by the sum of cylin-
ders method using a computer system (18). The variation of volume 
measurements ranged from 6.0 to 22.4%. The mean of three measure-
ments was used for further analysis of results. Plasma concentra-
tions of CCK and PP were measured by sensitive and specific ra-
dioimmunoassays (19i20,21). 
Plasma CCK (pmol/ 1 ) 
6 
30 60 90 
Time ( m m ) 
Figure 1 Effect of vivonex (open circles) and corn oil (closed 
circles) on plasma CCK concentrations in six healthy 
subjects. The asterisk denotes a significant difference 
between plasma CCK concentration after vivonex and corn 
oil at 10 min. 
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Results were expressed as the mean ± 1 SEM. Integrated CCK and 
PP secretion was determined by calculating the area under the 
curve after subtraction of basal value. Correlations were evalua­
ted by linear regression analysis. Student's t-test for paired 
results was used for statistical analysis. All subjects gave in­
formed consent before participating in the study. 
Results 
Ingestion of vivonex induced significant increases in plasma 
CCK concentration (fig. 1). Plasma CCK was significantly elevated 
over basal value at 5, 10, 15, 20, 25, 30, 40, 50 and 60 minutes 
after ingestion (p < 0.05 - ρ < 0.005). After ingestion of corn 
oil plasma CCK was significantly elevated over basal value at 5, 
10, 15, 20, 25, 30, 40, 50, 60 and 90 minutes (p < 0.05 - Ρ < 
0.0001). At 10 minutes after vivonex plasma CCK was significantly 
higher than that after corn oil (p < 0.05). However, neither peak 
increments (4.4 ± 0.6 pmol/1 after vivonex and 5.6 ± 0.8 pmol/1 
PlasmaPP(pmol/l ) 
30 
20 
10 
30 60 90 
Time (mm ) 
Figure 2 Effect of vivonex (open circles) and corn oil (closed 
circles) on plasma PP concentrations in six healthy sub­
jects. No significant differences between plasma PP con­
centrations after vivonex and corn oil were observed. 
105 
after corn oil), nor integrated CCK secretion (182.t ± 35.0 
pmol/1-90 m m after vivonex and 272.8 ± 63.1 pmol/1'90 min 
after corn oil) were significantly different. 
A slight increase in plasma PP concentration was observed af­
ter ingestion of vivonex (fig. 2 ) . Plasma PP was significantly 
elevated over basal value only in the 15 minutes postprandial 
sample (p < 0.05). Integrated PP secretion after vivonex (288 ± 
117 ριηο1/1·90 rain) was not significantly different from zero. 
Plasma PP response after corn oil showed a significant increase 
over basal value only at 50 minutes after ingestion, while inte­
grated PP secretion 323 ± 96 praol/1-90 min was significantly 
different from zero (p < 0.05) indicating a stimulatory effect of 
corn oil on PP release. No significant difference in time-respon­
se curve nor in integrated secretion was observed after ingestion 
of vivonex and corn oil. 
Both meals induced 
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g m f icantly 
< 0.01). However, 
ivonex (471 
from that 
± 103 cm3 
after corn 
Plasma CCK concentrations showed significant inverse correla­
tions with gallbladder volumes both after ingestion of vivonex 
(r = -0.8086; ρ < 0.01) and after ingestion of corn oil (r = 
-0.8455; ρ < 0.001). Similarly, a significant inverse correlation 
existed between plasma PP levels and gallbladder volumes after 
ingestion of corn oil (r = -7652; ρ < 0.01); but not after inges­
tion of vivonex (r = 0.5068; ρ > 0.05). Plasma PP levels were 
significantly correlated with plasma CCK levels after both meals 
(r = 0.6928; ρ < 0.05 after ingestion of corn oil; and r = 
0.7053; ρ < 0.05 after ingestion of vivonex). 
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Gallbladder volume (cm ) 
30 
25 -
20 
15 
10-
CJ meal 
30 60 90 Time ( min) 
Figure 3 Effect of vivonex (open circles) and corn oil (closed 
circles) on gallbladder volume as measured by ultrasono-
graphy in six healthy subjects. The asterisk denotes a 
significant difference between gallbladder volume after 
vivonex and corn oil at 40 min. 
Discussion 
Pancreatic enzyme secretion in response to oral or intraintes-
tinal administration of an elemental diet has been the subject of 
many studies (22-30). Some studies suggested a weak or absent 
stimulatory effect (22-27)! whereas others demonstrated a defi-
nite increase in pancreatic enzyme output (28-30). Species dif-
ferences, differences in composition of the elemental diet or 
technical difficulties in the assessment of pancreatic enzyme 
secretion in man after intraduodenal administration of nutrients 
may have accounted for these contrasting findings (31). At pre-
sent, no information is available on pancreatic exocrine respon-
ses to oral feeding of an elemental diet in man, mainly due to 
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difficulties in measurement of pancreatic exocrine function under 
such conditions. Furthermore, it is not known whether an elemen-
tal diet stimulates gallbladder contraction and what is the ef-
fect of such a diet on plasma CCK and PP, hormones with potent 
stimulatory and inhibitory effects, respectively, on both pan-
creatic enzyme secretion and gallbladder contraction. 
The present study showed that oral ingestion of an elemental 
diet stimulates plasma CCK secretion in man. Plasma CCK responses 
after ingestion of vivonex were comparable to those found after 
ingestion of 60 ml corn oil. Since the increments in plasma CCK 
observed in the present study were similar to those previously 
reported to strongly stimulate pancreatic enzyme secretion and 
gallbladder contraction during infusion of CCK into man (32), 
it can be derived that an elemental diet exerts potent stimula-
tory effects on pancreatic enzyme secretion and gallbladder con-
traction. Furthermore, plasma levels of PP, the only known hormo-
nal peptide which at physiological concentrations inhibits pan-
creatic secretion and gallbladder motility, showed only a minor 
increase after ingestion of vivonex. In fact, the present study 
showed that both corn oil and vivonex induced significant de-
creases in gallbladder volume which were inversely correlated 
with plasma CCK levels. All these findings suggest that CCK plays 
a major role in gallbladder contraction after vivonex. 
We have previously demonstrated that ingestion of carbohydrate 
does not stimulate CCK release (33). Furthermore, it is unlikely 
that the small quantity of fat (0.45 g) present in the vivonex 
meal accounted for the CCK release. L-essential amino acids, on 
the other hand, have been demonstrated to be strong stimulants of 
pancreatic enzyme secretion both in man (34) and in dog (35). 
Thus, the stimulatory effect of vivonex on plasma CCK is probably 
mediated by L-essential amino acids. It is interesting to note 
that as little as 2.37 g L-essential amino acids present in 80 g 
vivonex induce plasma CCK responses comparable to those seen af-
ter 60 ml corn oil or 50 g milk protein dissolved in 250 ml water 
containing 10 times more L-essential amino acids (33). The reason 
for this strong effect of vivonex is not known, but may be relat-
ed to a more ready availability of stimulating molecules to the 
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CCK-producing cells in the mucosa of the proximal gut. 
In order to prevent sludge and gallstone formation regular 
gallbladder emptying during nutritional support has been recom-
mended (10). In this respect enteral feeding of an elemental diet 
Integrated Integrated gallbladder 
plasma CCK contraction 
( p m o l / l 9 0 m i n ) (cnn3-90 m m ) 
Cornel l vivonex corn oil vivonex 
Figure 4 Integrated plasma cholecystokinin secretion (left panel) 
and integrated gallbladder contraction (right panel) 
after ingestion of corn oil and vivonex in six healthy 
subjects. 
seems preferable to total parenteral nutrition which may induce 
sludge and gallstone formation (10,11)36). On the other hand, the 
present study indicates that vivonex should not be recommended in 
patients in whom decreased pancreaticobiliary secretions are 
thought to be beneficial. 
In conclusion, oral ingestion of vivonex stimulates plasma CCK 
secretion and gallbladder contraction in man. 
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CHAPTER Χ 
COMPARATIVE STUDY OF THE EFFECTS OF TWO COMMERCIALLY AVAILABLE 
FATTY MEALS AND CHOLECYSTOKININ ON GALLBLADDER CONTRACTION AND 
PLASMA CONCENTRATIONS OF CHOLECYSTOKININ AND PANCREATIC 
POLYPEPTIDE 
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Abstract 
The present study was undertaken to compare the effects of two 
commercially available fatty meals and intravenously administered 
cholecystokinln (CCK) on gallbladder contraction and plasma con­
centrations of CCK and pancreatic polypeptide (PP). On separate 
mornings and in random order six healthy subjects ingested either 
Biloptin Fatty Meal or Sorbitract or received 1 Ivy dog unit/kg 
CCK as an intravenous bolus injection. Plasma CCK and PP concen­
trations were measured by sensitive and specific radioimmunoas­
says and gallbladder contraction by real-time ultrasonography. 
Mean fasting gallbladder volume was 26.0 ± 4.2 cm3. Maximal gall­
bladder contraction after Sorbitract (55 ± 6$) was reached at Ц0 
minutes, after Biloptin Fatty Meal (62 ± 7%) at 25 minutes and 
after CCK administration (48 ± 10Í) at 20 minutes. None of these 
differences reached statistical significance. Rate constants of 
gallbladder emptying were -0.0307 * 0.0071 min-1 for Sorbitract, 
-0.0428 ± 0.0080 min-1 for Biloptin Fatty Meal and -0.0375 ± 
0.0092 min-1 for CCK (NS). Ingestion of both fatty meals induced 
significant increases in plasma CCK concentration from a basal 
level of 2.5 ± 0.2 pmol/1 to 6.0 ± 0.9 pmol/1 after Sorbitract 
and 7.3 ± 1.0 pmol/1 after Biloptin Fatty Meal, while after admi-
nistration of CCK plasma CCK rose to a peak level of 277 ± 25 
pmol/1 at 5 minutes (p < 0.005 vs Sorbitract and ρ < 0.005 vs 
Biloptin Fatty Meal). Similarly, the plasma PP peak level after 
CCK (106 ± 17 pmol/1) was significantly higher than that after 
Sorbitract (41.0 ± 7.6 praol/1; ρ < 0.01) and that after Biloptin 
Fatty Meal (61.2 ± 13.9 praol/1; ρ < 0.05). 
It is concluded that intravenous injection of CCK does not 
induce a more rapid, predictable or effective gallbladder con­
traction than found after fatty meals, and that therefore there 
is no advantage in the use of CCK over ingestion of fatty meals 
in studying gallbladder contraction. 
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Introduction 
In oral cholecystography gallbladder contraction has been re­
commended for various reasons: 1) visualization of small stones, 
2) visualization of the cystic and common ducts, 3) to separate 
the gallbladder from overlying gas shadows, Ц ) diagnosis of ade-
nomyomatosis and cholesterolosis and 5) to differentiate a stone 
from a polyp (1-Ц). Furthermore, determination of gallbladder 
contraction may reveal motility disorders of the gallbladder, 
e.g. in acalculous gallbladder disease (5-7). However, the value 
of cholecystography in quantifying gallbladder contraction has 
been seriously questioned (8). Real-time ultrasonography, on the 
contrary, has been demonstrated to be an accurate and reproduci­
ble method for studying gallbladder volume and contraction in man 
(9). 
Different types of fatty meals have been used in the past to 
induce gallbladder contraction (10). Fatty meals are generally 
accepted to exert their action on the gallbladder by the release 
of cholecystokimn (CCK) from the proximal gut (1). When CCK and 
the octapeptide of CCK (CCK-OP) became available for intravenous 
injection to stimulate gallbladder contraction, fatty meals 
became less popular (1). One of the reasons to prefer CCK or 
CCK-OP was the assumption that they induced a more rapid and 
predictable gallbladder emptying (11-14). 
The purpose of the present study was to compare the effective­
ness and timing of gallbladder contraction, as determined by 
real-time ultrasonography, in response to intravenous bolus 
injection of CCK and two commercially available fatty meals. In 
order to further elucidate the mechanism of gallbladder contrac­
tion, the effect of the three stimulants on plasma concentrations 
of CCK and pancreatic polypeptide (PP) was determined. CCK is a 
powerfull stimulant of gallbladder contraction and this hormone 
is generally thought to play a crucial role in postprandial gall­
bladder contraction (1,15), whereas PP, a hormone released from 
the pancreas in response to feeding, is a strong inhibitor of 
gallbladder contraction (16,17). 
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Subjects and methods 
Six healthy volunteers (H male, 2 female; mean age 24 years, 
range 22-31 years) were studied. After an overnight fast on two 
separate mornings and in random order they ingested within 3 
minutes two different fatty meals. On a third morning 1 Ivy dog 
unit/kg CCK (Kabi Diagnostica, Studsvik, Sweden) was administered 
by slow intravenous infusion over a 1-minute period. The fatty 
meals ingested were Biloptin Fatty Meal (Schering AG, Berlin, 
Germany) containing 10 g dried egg yolk (3 g protein, 7 g fat) 
and 9 g Sorbitol, and Sorbitract (Dagra, Diemen, The Netherlands) 
containing 3 g fat, 6 g Sorbitol, 2.k g carbohydrate and 1.6 g 
protein. The Biloptin Fatty Meal was mixed with 75 ml water by 
stirring and ingested within one minute. The Sorbitract bar of 
chocolate was carefully masticated before swallowing. 
Blood samples for CCK and PP measurements were drawn at -5, 0, 
10, 15, 20, 25, 30, 35, 40, 50, 60, 75 and 90 minutes. After ad-
ministration of CCK an additional blood sample was obtained at 5 
minutes. Each time a blood sample was drawn three images of the 
gallbladder were made by real-time ultrasonography according to a 
previously described method (9,18). Gallbladder volume was calcu-
lated by the sum of cylinders method using a computerized system 
(9,18). The variation of volume measurements ranged from 6.0 to 
22.Uí (18). The mean of the three measurements was used for fur-
ther analysis of results. Plasma concentrations of CCK and PP 
were measured by sensitive and specific radioimmunoassays as pu-
blished previously (19,20,21). 
Results were expressed as the mean ± 1 SEM. Gallbladder volume 
was expressed in absolute values and as per cent of basal vo-
lume. Integrated CCK and PP secretion was determined by calcula-
ting the area under the curve after subtraction of basal value. 
The rate constant of gallbladder emptying was calculated by de-
termining the slope of the line obtained by linear regression 
analysis of the plot In Vt vs t (where Vt is gallbladder volume 
at time t). Statistical analysis was done by Student's t-test for 
paired results. Informed consent was obtained from all subjects 
studied. 
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Results 
Mean fasting gallbladder volume was 26.0 ± U · 2 cm3. Admini­
stration of all three stimulants induced significant decreases in 
gallbladder volume (fig. 1). At 10, 15, 20, 25, 30, 35, 40, 50 
and 60 minutes after Sorbitract, at 15, 20, 25, 30, 40, 50, 60 
and 75 minutes after Biloptin Fatty Meal and at 10, 15, 20, 25, 
30, 35, 40, 50, 60 and 75 minutes after intravenous CCK, gall­
bladder volume was significantly smaller than basal gallbladder 
volume (p < 0.05 - Ρ < 0.005; Ρ < 0.05 - Ρ < 0.005; Ρ < 0.05 - Ρ< 
0.005, respectively). Maximal gallbladder contraction after 
Gallbladder volume (cm3) 
3 0 
2 0 
10 
Sorbitract Biloptin fatly meal Cholecystokmin 
30 60 90 30 60 90 30 60 90 
Time (min) 
Figure 1 Gallbladder volume in response to oral ingestion of Sor-
bitract (left panel), to oral ingestion of Biloptin Fat­
ty Meal (middle panel) and to intravenous bolus injec­
tion of CCK (right panel). 
Sorbitract (55 ± 6Í) was reached at 40 minutes, after Biloptin 
Fatty Meal (62 ± 7%) at 25 minutes and after CCK administration 
maximal contraction was (48 * ΙΟί) reached at 20 minutes (fig. 
1). These differences were not statistically significant. Coef­
ficient of variation of maximal gallbladder contraction after CCK 
administration (21$) was not smaller than that after Sorbitract 
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(11Ï) or that after Biloptin Fatty Meal (11$). After ingestion of 
Sorbitract gallbladder volumes were not significantly different 
from those after Biloptin Fatty Meal or CCK. At 50 and 60 minutes 
after ingestion of Biloptin Fatty Meal gallbladder volume was 
significantly (p < 0.05) smaller than that after CCK (fig. 1). 
When expressed as per cent of basal value, gallbladder volumes at 
25 1 30, 50, 60 and 75 minutes after ingestion of Biloptin Fatty 
Meal were significantly smaller than after CCK (p < 0.05 - ρ < 
0.005). The rate constants of gallbladder emptying (-0.0307 ± 
0.0071 m m - 1 after Sorbitract, -0.0428 ± 0.0080 min-1 after 
Biloptin Fatty Meal, and -0.0375 ± 0.0092 min-1 after CCK) were 
not significantly different. 
Both fatty meals induced significant increases in plasma CCK 
concentrations (fig. 2). At 10, 15, 20, 25, 40, 50 and 90 minutes 
after ingestion of Sorbitract (p < 0.05 - ρ < 0.005), and at 10, 
15, 20, 25, 30, 35, 40 and 50 minutes after Biloptin Fatty Meal 
(p < 0.05 - ρ < 0.005) plasma CCK concentrations were signifi­
cantly elevated over basal value. At 15 minutes after Biloptin 
Fatty Meal plasma CCK was significantly higher than that after 
Sorbitract (p < 0.05). Furthermore, the increment of plasma CCK 
after Biloptin Fatty Meal (5.4 * 1.1 pmol/1) was significantly 
greater than that after Sorbitract (3.7 ± 0.9 pmol/1; ρ < 0.05). 
However, the peak plasma CCK levels after Biloptin Fatty Meal 
(7.3 ± 1.0 pmol/1) and after Sorbitract (6.0 * 0.9 pmol/1) were 
not significantly different. Also, the integrated plasma CCK 
secretions (252 ± 64 pmol/1-90 m m after Biloptin Fatty Meal, 
and 122 ± 74 pmol/l*90 m m ) did not significantly differ. As 
expected there was a rapid rise in plasma CCK concentration after 
intravenous bolus injection of the hormone. Plasma CCK rose from 
a basal value of 2.5 ± 0.4 pmol/1 to a peak level of 277 ± 25 
pmol/1 at 5 minutes after injection (fig. 2). This initial rise 
was followed by a rapid decline. Plasma CCK levels were signifi­
cantly elevated over basal value only at 5, 10, 15, 20 and 25 
minutes. After administration of CCK plasma levels were signifi­
cantly greater during the first 20 minutes when compared with 
Sorbitract (p < 0.05 - Ρ < 0.005), and during the first 15 minut­
es when compared with Biloptin Fatty Meal (p
 < 0.05 - ρ < 
ne 
0.005). Plasma CCK concentrations both after ingestion of Sorbi-
tract (r = -0.6667, ρ < 0.05) and after Biloptin Fatty Meal (r = 
-0.5813, ρ < 0.05) were significantly correlated with gallbladder 
volumes . 
Ingestion of sorbitract induced a slight increase in plasma PP 
concentrations (fig. 3), which reached statistical significance 
at 20 minutes only (p = 0.05). Biloptin Fatty Meal had a more 
powerful effect on plasma PP levels with significant increases 
over basal value at 25, 30, 35, 40, 60 and 75 minutes after 
ingestion. Plasma PP peak increments after Biloptin Fatty Meal 
(46.4 ± 12.7 pmol/1) were significantly greater than those after 
Plasma CCK (pmol/l)-
Sorbitract 
300 
Biloptin fatly meal 
2 5 0 
200-
100-
30 6 0 9 0 30 6 0 
—,0J 
90 
Cho'ecystokimn 
'T'— i-f-
30 60 90 
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Figure 2 Plasma CCK concentrations in response to oral ingestion 
of Sorbitract (left panel), to oral ingestion of 
Biloptin Fatty Meal (middle panel) and to intravenous 
bolus injection of CCK (right panel). 
Sorbitract (24.7 ± 8.0 pmol/1; ρ < 0.05). Similarly, PP peak le­
vels after Biloptin Fatty Meal (61.2 * 13.9 pmol/1) were signifi­
cantly higher than those after Sorbitract (41.0 ± 7.6 pmol/1; p< 
0.05). Integrated PP secretion after Biloptin Fatty Meal ( 1842 ± 
650 pmol/1'90 min) was not significantly different from that 
after Sorbitract (1332
 ± цдб pmol/l-go min). Plasma PP levels 
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after intravenous CCK (fig. 3) rose to a peak level of 106 ± 17 
pmol/1 at 10 minutes (p < 0.05 vs Biloptin Fatty Meal and < 0.01 
va Sorbitract). In all samples until 40 minutes plasma PP levels 
were significantly elevated over basal value (p 4 0.05 - ρ < 
0.005). PP peak increment after CCK (85.3 ± 11.6 pmol/1) was sig­
nificantly greater than that after Biloptin Fatty Meal (p < 0.05) 
and than that after Sorbitract (p < 0.005). Integrated plasma PP 
secretion 1752 ± 297 pmol/1, however, was not significantly dif­
ferent from that after the two oral stimulants. 
After intravenous administration of CCK all subjects experien­
ced transient mild abdominal discomfort, while both meals were 
without side-effects. 
Piscussion 
Previous studies have suggested that administration of CCK 
induces a more rapid and predictable gallbladder emptying than 
ingestion of stimulatory meals (12-11). In the present study no 
difference in emptying rate of the gallbladder after Biloptin 
Fatty Meal, Sorbitract and intravenous administration of CCK was 
observed. Moreover, Biloptin Fatty Meal tended to be more effec­
tive in inducing gallbladder contraction than intravenous bolus 
injection of CCK. It has been suggested that, besides the release 
of possible other cholecystogogues after a fatty meal, the longer 
duration of elevated concentrations of endogenous CCK in plasma 
may be the reason for this superiority (22). Indeed, the present 
study showed that plasma CCK levels were significantly elevated 
over basal value for a longer period of time after ingestion of 
Biloptin Fatty Meal than after CCK administration. The coeffi­
cient of variation of maximal contraction after intravenous admi­
nistration of CCK was not smaller than that after ingestion of 
the fatty meals indicating that CCK administration did not result 
in a more predictable gallbladder contraction. These results are 
at variance with a study using cholecystography in which it was 
demonstrated that CCK induced a more rapid gallbladder emptying 
(12). Differences in the technique to assess gallbladder contrac-
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tion or differences in the type of fatty meal used may have ac­
counted for this discrepancy (12). 
The good correlation between gallbladder volumes and plasma 
CCK suggests that both stimulants act by releasing CCK from the 
upper gastrointestinal mucosa. After intravenous administration 
of CCK plasma CCK rose to supraphysiological levels (23). Because 
neither emptying rate nor maximal contraction of the gallbladder 
after CCK differed from that after a fatty meal, it can be 
concluded that the supraphysiological plasma CCK levels do not 
induce a more rapid and effective gallbladder emptying. The 
reason for this may be sluggishness of gallbladder emptying, cys-
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Figure 3 Plasma PP concentrations in response to oral ingestion 
of Sorbitract (left panel), to oral ingestion of Bilop-
tin Fatty Meal (middle panel) and to intravenous bolus 
injection of CCK (right panel). 
tic duct spasm (25,26) or release of PP which has been demonstra­
ted to be a potent inhibitor of gallbladder contraction (16,17). 
Indeed, it was shown in the present study that pancreatic poly­
peptide levels after intravenous cholecystokimn were signifi­
cantly higher than those after the two fatty meals. 
Biloptin Fatty Meal and Sorbitract are without side-effects, 
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less expensive and more easy to administer than eholecystokimn . 
Furthermore, the various synthetic CCK preparations have the dis-
advantage of variation in activity (personal experience; 26). 
In conclusion, based on the present study it can be concluded 
that there is no reason to prefer the injection of CCK to the in-
gestion of fatty meals in stimulating gallbladder contraction in 
the examination of possible gallbladder disorders. 
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SUMMARY 
PLASMA CHOLECYSTOKININ AND GALLBLADDER RESPONSES TO NUTRIENTS 
IN MAN 
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Summary 
Choleoystokinin (CCK) is a polypeptide which is present both 
in tissue and plasma in different molecular forms. CCK has potent 
stimulatory effects on pancreatic enzyme secretion and gallblad-
der contraction. However, mainly due to the lack of a reliable 
method to quantitate circulating CCK levels, the physiological 
and pathophysiological significance of CCK in control of these 
and other gastrointestinal functions is only poorly understood. 
Using a recently developed sensitive and specific radioimmuno-
assay plasma CCK levels in response to various nutrients were de-
termined both in healthy subjects and in patients with upper gas-
trointestinal tract disorders. In order to further elucidate the 
role of CCK in mediating postprandial gallbladder contraction, 
plasma CCK levels and gallbladder volumes, as assessed by real-
time ultrasonography, were simultaneously monitored, as well in 
response to oral ingestion of various meals as during intravenous 
infusion of CCK resulting in physiological plasma CCK levels. 
In chapter II the effect of ingestion of pure nutrients on 
plasma CCK levels was studied in 8 healthy subjects. Ingestion of 
fat and protein induced significant increases in plasma CCK le-
vels. Peak increments in plasma CCK after ingestion of 50 g fat 
(4.8 ± 0.9 pmol/l) were not significantly different from those 
found after ingestion of 50 g protein (3·4 * 0.5 pmol/l). On the 
other hand, ingestion of 50 g starch did not significantly in-
fluence plasma CCK levels. This study showed that, in contrast to 
starch, fat and protein are potent stimuli for the release of 
CCK. 
Since the impairment of pancreatic enzyme secretion in res-
ponse to intraintestinai nutrients during administration of atro-
pine or after truncal vagotomy has been attributed to reduced CCK 
release, parasympathic-cholinergic control of CCK release was 
studied in chapters III and IV. Intraduodenal administration of 
60 ml corn oil m 6 normal subjects induced significant increases 
in plasma CCK concentrations. Intravenous administration of atro-
pine resulted in significant inhibition of plasma CCK secretion 
during the first 30 minutes after intraduodenal instillation of 
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corn oil. However, neither peak increments in plasma CCK (5.4 ± 
1.1 pmol/1 with atropine, 3.9 ± 0.9 pmol/1 without atropine) nor 
integrated plasma CCK secretions (2.69 ± 9.7 pmol/l-l80 min 
with atropine, 188 ± 66 ριηο1/1·ΐ8θ min without atropine) were 
significantly affected by atropine. Thus, administration of atro­
pine delayed , but did not inhibit the CCK response to intraduo­
denal corn oil in man. The mechanism of this delay is unknown, 
but may be related to initially slower emulsi fication and lipo-
lysis of triglycerides during administration of atropine resul­
ting in a diminished supply of stimulating digestive products to 
CCK producing cells. Absence of delay in CCK release following 
oral ingestion of Intralipid in patients with truncal vagotomy 
further supports this hypothesis, since in Intralipid triglyce­
rides are present as fine emulsified particles. 
Neural control of CCK release in response to nutrients is fur­
ther elucidated in chapter IV. In this chapter the plasma CCK 
response to oral ingestion of a liquid fat meal (250 ml 20Ï 
Intralipid) was studied in 6 patients with truncal vagotomy and 
pyloroplasty, 8 normal subjects, 6 patients with duodenal ulcer 
and 8 patients with highly selective vagotomy. Basal plasma CCK 
concentrations were not significantly different among the 4 
groups studied (2.1 ± 0.4 pmol/1 in normal subjects, 2.8 ± 0.5 
pmol/1 in duodenal ulcer patients , 3.I ± 0.5 pmol/1 in patients 
with truncal vagotomy and 2.7 * 0.5 pmol/1 in patients with high-
ly selective vagotomy). The peak increments in plasma CCK after 
ingestion of the fat meal in patients with truncal vagotomy (15.7 
± 3.1 pmol/1) or highly selective vagotomy (14.9 ± 1.6 pmol/1) 
were significantly higher than those in normal subjects (4.8 ± 
0.9 pmol/1) and in patients with duodenal ulcer (5.5 ± 0.6 
pmol/1). Similarly, the integrated plasma CCK secretions in pa-
tients with truncal vagotomy (554 ± 139 pmol/l*120 rain) and in 
patients with highly selective vagotomy (876 ± 132 pmol/l*120 
min) were significantly increased compared to those in normal 
subjects (187 ± 29 pmol/1'120 min) and in patients with duode-
nal ulcer (264 ± 35 pmol/1'120 m m ) . It can therefore be con-
cluded that patients with either truncal vagotomy or highly 
selective vagotomy show an increased plasma CCK secretion m res-
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ponse to a liquid fat meal, whereas the CCK secretion in patients 
with duodenal ulcer Is similar to that in normal subjects. There-
fore, vagotomy does not impair the plasma CCK secretion in res-
ponse to nutrients. It is unlikely that the increased CCK respon-
se after truncal vagotomy results from vagal denervation of the 
proximal small bowel, because this increased réponse is also ob-
served in patients with highly selective vagotomy. The mechanism 
of the increased CCK secretion is probably related to the rapid 
gastric emptying of liquids in these patients resulting in a 
greater segment of gut exposed to luminal stimulants. 
Cholecystokinin is produced by endocrine cells in the mucosa 
of the upper small intestine. Since the highest concentrations of 
CCK are found in the duodenal mucosa, it is possible that food 
bypassing the duodenum will result in a reduced CCK release. 
Therefore, in chapter V plasma CCK response to oral ingestion of 
a liquid fat meal (250 ml 20% Intralipid) was studied in 7 pa-
tients with Billroth II gastrectomy, six patients with Billroth I 
gastrectomy and nine normal subjects. Fasting plasma CCK concen-
trations in patients with Billroth II gastrectomy (2.6 * 0.4 
pmol/1) and in patients with Billroth I gastrectomy (2.9 * 0.5 
pmol/1) were not significantly different from those in normal 
subjects (1.9 ± 0.3 pmol/1). Ingestion of the fatty meal induced 
similar increments in plasma CCK in patients with Billroth II 
gastrectomy (10.2 ± 2.4 pmol/1) as in patients with Billroth I 
gastrectomy (8.4 ± 1.1 pmol/1). However, the increments in plasma 
CCK in patients with gastrectomy were significantly greater than 
those in normal subjects (4.1 ± 0.7 pmol/1). Similarly, the inte-
grated plasma CCK secretion in the patients with partial gastrec-
tomy was significantly greater than that in the normal subjects, 
while the integrated plasma CCK secretion in patients with Bill-
roth II gastrectomy (458 ± 69 pmol/l-120 min) was similar to 
that in patients with Billroth I gastrectomy (365 ± 61 pmol/1· 
120 min). The study indicated that large amounts of CCK can be 
released from the jejunum and that bypassing the duodenum does 
not affect plasma CCK secretion after ingestion of fat. As in pa-
tients with truncal vagotomy the increased CCK secretion in pa-
tients with partial gastrectomy is probably related to the rapid 
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gastric emptying of meals in such patients. Since infusion of 
high doses of CCK stimulates small intestinal motility, it may be 
possible that the high postprandial plasma CCK concentrations 
contribute the pathogenesis of the postgastrectomy syndrome, as 
sometimes found in such patients. 
For physiological and clinical studies of gallbladder motility 
reliable measurement of gallbladder volume is required. Real-time 
ultrasonography and calculation of gallbladder volume by the sum 
of cylinders method provides a simple, accurate and noninvasive 
method for studying gallbladder size and motility m intact man. 
In this method at regular intervals (e.g. every 5 minutes after a 
stimulus) images of the gallbladder are obtained by a real-time 
scanner. In order to safe time a computerized method for rapid 
quantification of gallbladder volume from real-time sonographs 
was developed (chapter VI). The time required to calculate gall-
bladder volume by this method was only one to two minutes compar-
ed to eight to twelve minutes using the by hand method. The coef-
ficient of variation of 6 calculations of 3 gallbladder volumes 
ranged from 6.2 to 10.0Í, while the coefficient of variation of 
measurements of 3 gallbladder volumes obtained within 5 minutes 
in each of 6 fasting subjects was between 6.0 and 22.1)%. There 
was a highly significant correlation between gallbladder volumes 
calculated by computer and by hand methods (r = 0.97; Ρ < 
0.001). The computerized method allowed rapid and reproducible 
determination of gallbladder volume and contraction using real­
time ultrasonography in man. 
Measurement of gallbladder contraction by ultrasonography was 
compared to measurement of gallbladder contraction by intraduode-
nal bilirubin output during infusion of stepwise increasing "phy­
siological" doses of CCK in man (chapter VII). Infusion of 0.2, 
0.4, 0.8, 1.6, 3·2 and 6.4 pmol/kg-hr CCK33 induced stepwise 
increases in plasma CCK from a basal value of 1.7 ± 0.2 pmol/1 to 
a level of 6.9 ± 0.8 pmol/1 during the 6.4 pmol/kg-hr dose. At 
the same time, stepwise decreases in gallbladder volume were ob­
served from a fasting volume of 28.8 * 2.5 cm3 to a residual 
volume of 6.3 ± 1.4 cm3 during infusion of the highest dose. The 
correlation between intraduodenal bilirubin outputs and decreases 
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in gallbladder volumes was highly significant (r = 0.9773; ρ < 
0.001). Infusion of 0.8 pmol/kg-hr CCK33, resulting in an in­
crease in plasma CCK of 1.3 ± 0.5 pmol/1, was the threshold for 
stimulating gallbladder contraction as assessed by both methods. 
This indicates that ultrasonography is equally sensitive and 
accurate in the quantification of gallbladder contraction as 
measurement of intraduodenal bilirubin output and that because of 
its simplicity ultrasonography is the preferred method for study­
ing gallbladder contraction. Moreover, since the increments in 
plasma CCK were and the subsequent gallbladder contractions were 
comparable to those found after a meal, this study points to an 
important role of CCK in postprandial gallbladder contraction. 
In chapter VIII the effects of equimolar amounts of long-chain 
triglycerides (LCT) and medium-chain triglycerides (MCT) on plas­
ma CCK and gallbladder contraction have been compared in 6 heal­
thy subjects. Ingestion of LCT induced significant increases in 
plasma CCK from 2.8 ± 0.5 to 6.5 ± 0.7 pmol/1 and decreases in 
gallbladder volume from 33.4 ± 5.9 to 13.2 ± 4.2 cm3. On the 
other hand, no significant changes in plasma CCK and gallbladder 
volume were observed after ingestion of MCT in the same sub­
jects. Ingestion of MCT was followed by abdominal cramps and dia­
rrhoea in all subjects studied. The diarrhoea may have resulted 
from impaired hydrolysis of MCT due to the lack of stimulation of 
pancreatic enzyme secretion in the absence of CCK secretion. 
In chapter IX oral ingestion of 80 g Vivonex dissolved in 300 
ml water on plasma CCK and pancreatic polypeptide (PP) secretion 
and on gallbladder contraction was studied in 6 healthy sub­
jects. At physiological plasma levels PP inhibits both gallblad­
der contraction and pancreatic enzyme secretion. Ingestion of 
Vivonex was followed by significant increases in plasma CCK. Peak 
increment of plasma CCK after vivonex ( 4. 1| ± 0.6 pmol/1) was not 
significantly different from that after oral ingestion of corn 
oil (5.6 ± 0.8 pmol/1). Vivonex had only a minor effect on plasma 
PP level. Gallbladder volume decreased significantly after inges­
tion of vivonex to a maximal contraction of 51 * 10%. Both after 
vivonex (r = -0.8086; ρ < 0.01), and after corn oil (r = -0.8455; 
ρ < 0.001) a significant inverse correlation between plasma CCK 
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levels and gallbladder volumes was observed , supplying further 
evidence for an important role of CCK in postprandial gallbladder 
contraction. Since the increments in plasma CCK were comparable 
to those previously reported to strongly stimulate pancreatic 
enzyme secretion it can be derived that vivonex exerts potent 
stimulatory effects on pancreatic enzyme secretion as well. This 
study indicates that vivonex should not be recommended in pa-
tients in whom decreased pancreaticobiliary secretions are 
thought to be beneficial. 
Finally, in chapter X the effects of two commercially availa-
ble fatty meals (Biloptin Fatty Meal, Sorbitract) and intrave-
nously administered bolus injection of CCK on gallbladder con-
traction and plasma concentrations of CCK and PP were studied. 
There was no advantage in the injection of CCK over ingestion of 
fatty meals in studying gallbladder motility. Both rate constants 
of gallbladder emptying and maximal gallbladder contractions were 
smimilar after administration of the three stimulants. Further-
more, this study revealed that supraphysiological plasma CCK 
levels, as observed after intravenous administration of CCK, do 
not contribute to a more rapid and effective gallbladder empty-
ing . 
In conclusion, the work presented in this thesis shows that 
postprandial secretion of CCK is dependent on the type of nu-
trients applied and the anatomy of the upper gastrointestinal 
tract. It further demonstrates that circulating CCK is an impor-
tant factor in postprandial gallbladder contraction. 
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SAMENVATTING 
HET EFFECT VAN TOEDIENING VAN VOEDINGSSTOFFEN 
OP DE PLASMA CHOLECÏSTOKININESPIEGEL 
EN DE GALBLAASCONTRACTIE 
BIJ DE MENS 
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Samenvatting 
Cholecystokinine (CCK) із een polypeptide, dat zowel in weef­
sels als in plasma aanwezig is in verschillende moleculaire vor­
men. CCK heeft een krachtig stimulerende werking op de pancreas-
enzymsecretie en op de galblaascontractie. Vooral door het ont­
breken van een betrouwbare bepalingsmethode voor plasma spiegels 
van CCK is weinig bekend over de fysiologische en pathofysiolo-
gische betekenis van CCK bij de regulatie van deze en andere gas­
trointestinale functies. Met een recent ontwikkelde, sensitieve 
en specifieke radioimmunobepaling werden plasma CCK-spiegels na 
orale of entérale toediening van verscheidene voedingsstoffen be-
paald, zowel bij gezonden als bij patiënten met afwijkingen in 
het bovenste deel van de tractus digestivus. De betekenis van CCK 
bij de postprandiale galblaascontractie werd onderzocht door te-
gelijkertijd plasma CCK-spiegels en galblaasvolumina te bepalen, 
zowel na het nuttigen van diverse maaltijden als tijdens infusie 
van fysiologische doses CCK. 
In hoofdstuk II werd het effect van maaltijden bestaande uit 
zuivere voedingsstoffen op de plasma CCK-spiegel bestudeerd bij 8 
gezonde personen. Orale opname van vet induceerde significante 
stijgingen van de plasma CCK-concentratie. Piekst ijgingen van het 
plasma CCK na een maaltijd bestaande uit 50 g vet ( 14.8 ± 0.9 
pmol/1) waren vergelijkbaar met de piekstijgingen na 50 g eiwit 
(3.4 ± 0.5 pmol/1), terwijl 50 g zetmeel géén significante in-
vloed had op het CCK-gehalte. Deze studie toont aan dat vet en 
eiwit potente stimuli voor de CCK-secretie zijn, in tegenstelling 
tot zetmeel . 
De remming van de door intraintestinale voedingsstoffen gesti-
muleerde pancreasenzyrasecretie tijdens intraveneuze toediening 
van atropine of na trúncale vagotomie is wel toegeschreven aan 
een remming van de CCK-secretie. De cholinerge en parasyrapa-
thische regulatie van de CCK-secretie werd daarom bestudeerd 
(hoofdstuk III en IV). Na intraduodenale toediening van 60 ml 
maisolie aan 6 gezonde personen traden significante stijgingen 
van de plasma CCK-concentratie op. Intraveneuze toediening van 
atropine resulteerde in significant lagere plasma CCK-concentra-
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ties tot 30 minuten na intraduodenale toediening van maisolie. De 
piekstijgingen van het plasma CCK (5.Ί ± 1.1 pmol/1 met atropine; 
З.9 ± 0.9 pmol/1 zonder atropine) en de geïntegreerde plasma 
CCK-respons (269 ± 97 pmol/l-iSO m m met atropine; 188 ± 66 
pmol/l-l80 min zonder atropine) werden echter m e t significant 
beïnvloed door atropine. Tijdens atropine trad er dus een vertra-
ging, maar géén remming van de CCK-respons na intraduodenaal toe-
gediende maisolie op. Het mechanisme achter deze vertraging houdt 
mogelijk verband met de in het begin langzamere emulgenng en 
lipolyse van triglycenden tijdens atropine, met als gevolg een 
kleiner aanbod van stoffen die CCK-producerende cellen stimu-
leren. De afwezigheid van deze vertraging in de CCK-secretie na 
het drinken van 250 ml Intralipid bij patiënten met trúncale 
vagotomie ondersteunt deze hypothese, omdat in Intralipid de tri-
glyceriden aanwezig zijn als fijne, geémulgeerde deeltjes. 
De neurale regulatie van de door voedingsstoffen gestimuleerde 
CCK-secretie werd in hoofdstuk IV verder onderzocht. In dit 
hoofdstuk werd de plasma CCK-respons bestudeerd na het drinken 
van een vloeibare vetmaaltijd (250 ml 20Í Intralipid) bij 6 
patiënten met trúncale vagotomie, 8 gezonde personen, 6 patiënten 
met ulcus duodeni en 8 patiënten met hoogselectieve vagotomie. 
Er waren geen significante verschillen in basale plasma CCK-con-
centraties tussen de 4 onderzochte groepen (2.1 ± 0.1 pmol/1 bij 
gezonden, 2.8 ± 0.5 pmol/1 bij patiënten met ulcus duodeni, 3.I ± 
0.5 pmol/1 bij patiënten met trúncale vagotomie en 2.7 * 0.5 
pmol/1 bij patiënten met hoogselectieve vagotomie). De piekstij-
gingen van het plasma CCK-gehalte na de vetmaaltijd bij patiënten 
met trúncale vagotomie (15.7 ± 3.1 pmol/1) of hoogselektieve 
vagotomie (14.9 ± 1.6 pmol/1) waren significant groter dan die 
bij gezonde personen (Ц.8 ± 0.9 pmol/1) en die bij patiënten met 
ulcus duodeni (5.5 ± 0.6 pmol/1). Ook de geïntegreerde plasma 
CCK-respons was bij patiënten met trúncale vagotomie (554 ± 139 
pmol/1· 120 min) en bij patiënten met hoogselectieve vagotomie 
(876 ± 132 pmol/1'120 min) significant groter dan die bij ge-
zonde personen (I87 ± 29 pmol/1'120 min) en bij patiënten met 
ulcus duodeni (264 ± 35 pmol/1'120 min). Hieruit kan geconclu-
deerd worden dat patiënten met een trúncale of een hoogselectieve 
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vagotomie een toegenomen CCK-secretie hebben na een vloeibare 
vetmaaltijd, terwijl de CCK-secretie bij patiënten met een ulcus 
duodeni vergelijkbaar is met die bij gezonde personen. Vagotomie 
remt daarom de plasma CCK-secretie onder invloed van voedings-
stoffen niet. Het is onwaarschijnlijk dat de toegenomen CCK-
secretie na trúncale vagotomie het gevolg is van vagale denerva-
tie van de proximale dunne darm, omdat deze toegenomen secretie 
ook wordt gezien bij patiënten met een hoogselectieve vagotomie. 
De toegenomen CCK-secretie wordt waarschijnlijk veroorzaakt door 
de snelle maagontlediging van vloeistoffen bij patiënten met een 
trúncale of hoogselectieve vagotomie, zodat in een groter darm-
segment CCK-producerende cellen worden geprikkeld door stimule-
rende stoffen. 
CCK wordt geproduceerd door endocriene cellen in de mucosa van 
het proximale deel van de dunne darm. Omdat de hoogste concentra-
ties CCK worden gevonden in de mucosa van het duodenum, is het 
mogelijk dat kortsluiting van het duodenum voor de voedselbnj 
resulteert in een verminderde CCK-secretie. Daarom werd in hoofd-
stuk V het effect van een vloeibare vetmaaltijd (250 ml 20% 
Intralipid) op de plasma CCK-spiegel bestudeerd bij 7 patiënten 
met een partiële maagresectie en een Billroth II-anastomose, bij 
6 patiënten met een partiele maagresectie en een Billroth I-ana-
storaose en bij 9 gezonde personen. De nuchtere CCK-spiegel bij 
patiënten met een Billroth II-maagresectie (2.6 ± 0.4 pmol/1) en 
bij patiënten met een Billroth I-maagresectie (2.9 ± 0.5 pmol/1) 
was niet verschillend van die bij gezonde personen. De vetmaal-
tijd induceerde plasma CCK-stιjgingen bij patiënten met een Bill-
roth II-maagresectie (10.2 ± 2.4 pmol/1) die vergelijkbaar waren 
met die bij patiënten met een Billroth I-maagresectie (8.4 ± 1.1 
praol/1). De plasma CCK-stijgingen bij de patiënten met een par-
tiële maagresectie waren significant groter dan die bij gezonde 
personen (4.1 ± 0.7 pmol/1). Ook was de geïntegreerde plasma 
CCK-respons bij patiënten met een partiële maagresectie signifi-
cant groter dan die bij gezonde personen, terwijl de geïntegreer-
de CCK-respons bij patiënten met een Billroth II-maagresectie 
(458 ± 69 ρπιο1/1·120 min) vergelijkbaar was met die bij patiën-
ten met een Billroth I-raaagresectie (365 * 61 pmol/1-120 min). 
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Deze studie wijst erop dat grote hoeveelheden CCK kunnen worden 
geseoerneerd in het jejunum en dat kortsluiting van het duodenum 
géén invloed heeft op de CCK-secretie na een vloeibare vetmaal-
tijd. Evenals bij patiënten met een trúncale vagotomle houdt de 
toegenomen CCK-secretie bij patiënten met een partiële maagreseo-
tie waarschijnlijk verband met de snelle maagontlediging van 
maaltijden bij deze patiënten. Omdat infusie van hoge doses CCK 
de motiliteit van de dunne darm stimuleert, is het mogelijk dat 
de hoge postprandiale CCK-spiegels bijdragen tot de Pathogenese 
van het postgastreetomiesyndroom, dat bij deze patiënten kan 
voorkomen . 
Voor fysiologische en klinische studies van galblaasmoti1iteit 
is het gewenst de beschikking te hebben over een betrouwbare 
meettechniek voor galblaasvoluraina. Real-time echografie en bere-
kening van galblaas Volumina met de som-van-cylinders-methode is 
een eenvoudige, accurate en met-invasie ve techniek voor in vivo 
bepaling van galblaasvolume en galblaascontract ie bij mensen. Bij 
deze methode worden op regelmatige tijden (bijv. elke 5 minuten 
na toediening van een stimulus) echogrammen gemaakt van de gal-
blaas met een real-time scanner. Ora tijd te sparen werd een 
gecomputeriseerde methode voor snelle berekening van galblaas-
volumina uitgaande van real-time echogrammen ontwikkeld (hoofd-
stuk VI). De tijd die nodig was voor de berekening van één gal-
blaasvolume met de computer bedroeg slechts één tot twee minuten, 
terwijl berekening van één galblaasvolume met de hand θ tot 12 
minuten vergde. De variatiecoëfficiënt van 6 berekeningen van 3 
galblaasvolumina varieerde van 6.2 tot 10.0$, terwijl de varia-
tiecoëfficiënt van metingen van 3 galblaasvolumina verkregen bin-
nen 5 minuten bij ieder van 6 personen 6.0 - 22.4% bedroeg. Er 
bestond een uitstekende correlatie tussen galblaasvolumina bere-
kend met de hand en galblaasvolumina berekend met de computer 
(r = 0.97; ρ < 0.001). De gecomputeriseerde methode bood dus de 
mogelijkheid tot snelle en reproduceerbare meting van galblaas­
volume en galblaascontractie met behulp van echografie bij men­
sen. Meting van galblaascontract ie met echografie werd vergeleken 
met meting van galblaascontractie met intraduodenale output van 
bilirubine tijdens infusie van stapsgewijs toenemende "fysiolo-
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gische" doses CCK bij gezonde vrijwilligers (hoofdstuk VII). 
Infusie van 0.2, 0. 4, 0.8, 1.6, 3.2 en 6.4 pmol/kg-hr CCK33 
resulteerde in stapsgewijze stijgingen van de plasma CCK-spiegel 
van een basale waarde van 1.7 ± 0.2 pmol/1 tot een niveau van 6.9 
± 0.8 pmol/1 tijdens infusie van de 6.Ц pmol/kg-hr dosis. Tege­
lijkertijd werd het galblaasvolume stapsgewijs kleiner van een 
nuchter volume van 28.8 ± 2.5 cm3 tot 6.3 ± 1.4 cm3. De correla­
tie tussen intraduodenale bilirubine output en daling van het 
galblaas volume was hoogsignificant (r = 0.9773; Ρ < 0.001). Infu­
sie van 0.8 pmol/kg-hr CCK33, resulterende in een plasma CCK-
stijging van 1.3 ± 0.5 pmol/1, was de drempel voor stimulering 
van de galblaascontractie als gemeten met beide technieken. Deze 
gegevens wijzen erop dat real-time echografie een even gevoelige 
en accurate techniek is voor kwantificering van galblaascontrac-
tie als meting van de intraduodenale bilirubine-output en dat, 
vanwege zijn eenvoud, real-time echografie de voorkeur verdient 
voor bestudering van galblaascontract ie. Omdat de stijgingen van 
de plasma CCK-concentratie en de daarop volgende galblaascontrac­
ties vergelijkbaar waren met die na een maaltijd, wijst deze stu­
die bovendien op een belangrijke rol van CCK bij de postprandiale 
galblaascontractie. 
In hoofdstuk VIII werden de effecten van equimolaire hoeveel­
heden long-chain triglycerides (LCT) en medium-chain triglyce­
rides (MCT) op het plasma-CCK en de galblaascontract ie vergeleken 
bij 6 gezonde personen. Orale opname van LCT resulteerde in sig­
nificante stijgingen van het plasma CCK van 2.8 ± 0.5 tot 6.5 ± 
0.7 pmol/1 en dalingen van het galblaasvolume van 33.4 ± 5.9 tot 
13.2 * 4.2 cm3. Daarentegen werden geen significante verande­
ringen waargenomen in het plasma CCK en het galblaasvolume na 
orale opname van MCT bij dezelfde personen. Na MCT kregen alle 
personen wel buikkrampen en diarree. Mogelijk ontstond de diarree 
door gebrekkige hydrolyse van MCT als gevolg van het ontbreken 
van stimulering van de pancreasenzyrasecretie door afwezigheid van 
CCK-secretie. 
In hoofdstuk IX werd de galblaascontractie en de plasma chole-
cystokimne- en plasma pancreaspolypept iderespons na orale toe­
diening van 80 g Vivonex , opgelost in 300 ml water, bij 6 gezonde 
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vrijwilligers bestudeerd. Bij fysiologische plasma spiegels remt 
pancreaspolypeptide (PP) zowel galblaascontraotie als pancreasen-
zymsecretie. Na orale opname van Vivonex traden significante 
stijgingen van de plasma CCK-spiegel op. De piekstijging van CCK 
na Vivonex (4.4 ± 0.6 pmol/1) was niet significant verschillend 
van die na orale opname van maisolie (5.6 ± 0.8 pmol/1) bij de­
zelfde personen. Vivonex had weinig effect op de plasma PP-spie-
gel. Het galblaasvolurae daalde significant na Vivonex. De maxima­
le contractie was 51 ± ioj{. Zowel na Vivonex (r = -0.8086; ρ < 
0.01) als na maisolie (r = -0.8455; Ρ < 0.001) bestond er een 
significante negatieve correlatie tussen plasma CCK-spiegels en 
galblaasvolumina. Deze correlatie verschaft verder bewijs voor 
een belangrijke rol van CCK bij het optreden van galblaascontrac-
tie na een maaltijd. De stijgingen van het plasma CCK waren ver­
gelijkbaar met die, waarvan bekend is dat ze gepaard gaan met een 
sterke stimulering van de pancreasenzymsecret ie. Hieruit kan wor­
den afgeleid dat Vivonex ook een sterk stimulerend effect op de 
pancreasenzymseeretie heeft. Deze studie wijst erop dat Vivonex 
niet moet worden aangeraden aan patiënten bij wie gestreefd wordt 
naar een verminderde pancreasenzymseeretie en/of galblaascontrac-
tie. 
Tenslotte werden de effecten van twee commercieel verkrijgbare 
vetmaaltijden (Sorbitract en Biloptin Fatty Meal) en intraveneuze 
bolus injectie van CCK op galblaascontractie en plasmaconcentra-
ties van CCK en PP bestudeerd. Intraveneuze toediening van CCK 
had géén voordelen boven orale toediening van deze vetmaaltijden 
bij de bestudering van galblaascontractie. Zowel de snelheidscon-
stante voor galblaasontlediging als de maximale galblaascontrac-
tie waren vergelijkbaar na de drie stimuli. Verder wees deze stu-
die erop dat suprafysiologische CCK-spiegels, zoals deze optreden 
na een CCK-bolus, niet bijdragen tot een snellere en effectievere 
galblaascontract ie . 
Conclusie: de studies beschreven in dit proefschrift tonen aan 
dat de postprandiale secretie van CCK afhangt van de aard van de 
toegediende voedingsstof en van de anatomie van het bovenste deel 
van de tractus digestivus. Verder tonen zij aan dat in het bloed 
circulerend CCK een belangrijke factor is bij de postprandiale 
galblaascontractie . 
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STELLINGEN 
1 Aminozuuroplossingen stimuleren de pancreasenzymsecretie. 
Hiermee dient men rekening te houden bij het voorschrijven 
van parenterale voeding aan patiënten met een pancreatitis. 
2 Cholecystokinine is de belangrijkste factor bij de postpran-
diale galblaascontractie. 
3 Met behulp van real-time echografie en een gecomputeriseerde 
berekeningsmethode is het mogelijk snel en reproduceerbaar 
galblaasvolumina en galblaascontractie te bepalen. 
Dit proefschrift 
4 Kortsluiting van het duodenum voor de voedselbrij, zoals bij 
een Billroth Il-maagresectie, leidt niet tot een verminderde 
cholecystokininesecretie na een vloeibare vetmaaltιjd. 
Dit proefschrift 
5 Omeprazol is een aanwinst bij de behandeling van aan maagzuur 
gerelateerde afwijkingen. 
- Laraers CBHW, Lind T, Moberg S, Jansen JBMJ, Olbe L. Omepra­
zole in Zollinger-Ellison syndrome. N Engl J Med 1984; 310: 
758-61 . 
6 Bij de diagnostiek van galblaasziekten verdient real-time 
echografie als eerste onderzoek de voorkeur. 
- Cooperberg PL, Burhenne HJ. Real-time ultrasonography. 
Diagnostic technique of choice in calculous gallbladder 
disease. N Engl J Med 198O; 302: 1277-9. 
- De Lacey G, Gajjer B, Twomey B, Levi J, Cox AG. Should 
cholecystography or ultrasound be the primary investigation 
for gallbladder disease? Lancet 1984; I: 205-7. 
7 Het verwijzen naar literatuur in een artikel zonder tegelij­
kertijd een lijst van referenties toe te voegen, hetgeen 
o.a. gebeurt in het Geneesraiddelenbulletin, is een minachting 
van de lezer . 
Protocollaire geneeskunde stimuleert niet het kritisch denken 
van de arts en het is daarom de vraag of deze manier van ge-
neeskunde bedrijven ten goede komt aan de patiënt en de kos-
ten van de gezondheidszorg vermindert. 
Daar de criteria voor het verkrijgen van het predikaat "cum 
laude" voor een proefschrift per universiteit, per faculteit 
en per afdeling kunnen wisselen, is de betekenis van dit pre-
dikaat zeer twijfelachtig. 
Het Binnenvaartpolltiereglement, dat op 1 april 1984 van 
kracht is geworden, bevat te veel en te onduidelijke voor-
schriften voor de pleziervaart en past niet in het streven 
van de huidige regering naar deregulering. 
Het star hanteren van leeftijdsgrenzen o.a. bij de toekenning 
van subsidies aan wetenschappelijk onderzoekers, heeft tot 
gevolg dat diegenen worden benadeeld, die taken ten dienste 
van de gemeenschap hebben verricht. 
Het plaatsen van 48 sexbommen in plaats van 48 kruisraketten 
is een gebaar van goede wil, zowel naar het Warschau Pact als 
naar de NAVO. 


